CMLS, Cell. Mol. Life Sci. 58 (2001) 4–43
1420-682X/01/010004-40 $ 1.50 + 0.20/0
© Birkhäuser Verlag, Basel, 2001

CMLS Cellular and Molecular Life Sciences

Review

The CD40/CD154 receptor/ligand dyad

U. Schönbeck* and P. Libby

Cardiovascular Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, 221 Longwood Ave., LMRC 307, Boston (Massachusetts 02115, USA), Fax + 1 617 732 6961, e-mail: uschoenbeck@rics.bwh.harward.edu

Received 10 January 2000; received after revision 16 June 2000; accepted 5 July 2000

Abstract. Until recently, the expression and primary function of the cell surface receptor CD40 and its ligand CD154 were considered restricted to B and T lymphocytes, and their interactions required for the thymus-dependent humoral response. However, current work from several groups challenges this view of the CD40/CD154 dyad as a mere mediator of lymphocyte communication. A variety of non-lymphocytic cell types express both receptor and ligand, including hematopoetic and non-hematopoetic cells, such as monocytes, basophils, eosinophils, dendritic cells, fibroblasts, smooth muscle, and endothelial cells. Accordingly, ligation of CD40 mediates a broad variety of immune and inflammatory responses, such as the expression of adhesion molecules, cytokines, matrix-degrading enzymes, prothrombotic activities, and apoptotic mediators. Consequently, CD40 signaling has been associated with pathogenic processes of chronic inflammatory diseases, such as autoimmune diseases, neurodegenerative disorders, graft-versus-host disease, cancer, and atherosclerosis. This review focuses on the synthesis and structure of CD40 and outlines CD154/CD40 signaling pathways, and emphasizes the previously unexpected importance of the CD40/CD154 receptor/ligand dyad in a spectrum of immunoregulatory processes and prevalent human diseases.

Key words. CD154; CD40; immunity; inflammation; arteriosclerosis.

1. Introduction to the CD40/CD154 dyad

Since its original discovery more than a decade ago, the CD40/CD40L receptor/ligand dyad has received increasing interest in the scientific community, as demonstrated by the steadily increasing number of publications (initiating in 1986 with 1 report, the number of Medline-listed publications increased to 594 in 2000, totaling 3026 reports on CD40, CD40L, CD154, Bp50, CDw40). CD40 was originally discovered in immunohistochemical studies employing an antibody detecting a 50-kDa protein (originally termed Bp50) on the surface of B lymphocytes [1–3]. Those early studies revealed that the expression level of this molecule varied with the status of B cell activation, fluctuating with progression through the cell cycle as well as with B lymphocyte differentiation and survival upon ligation of a then unknown ligand [4]. Later studies showed that this activation of B lymphocytes required direct contact with T helper cells rather than soluble lymphokines [5, 6]. Further work showed that the B lymphocyte-activating function required de novo protein synthesis, and followed stimulation by anti-CD3 antibodies, phorbol myristate acetate (PMA), or concanavalin A [7]. Moreover, early studies showed that the T helper cell induced B cell cycle entry into G1 did not result from an increase in expression of then recognized surface markers, such as CD3, CD4, LFA-1, intracellular adhesion molecule (ICAM)-1, class I major histocompatibility

* Corresponding author.

complex (MHC) molecules or Thy-1. Ultimately, the identity of the polycolonal, antigen-non-specific, and MHC-unrestricted B cell activation triggered by activated T helper cells via a non-polymorphic cell surface molecule was elucidated by cloning of the murine and human ligand for CD40, termed CD154 [previously also referred to as CD40 ligand (CD40L), gp39, TRAP, or TBAM], an integral membrane protein thought restricted to activated CD4 + helper T cells [8–12].
Further studies on the biological function of the receptor/ligand dyad established interactions of CD154 with its receptor CD40 on B lymphocytes as a crucial process in T cell-dependent B cell differentiation and activation [13]. Further evidence for this conclusion was provided by studies employing blocking antibodies which prevented an immune response to T cell-dependent antigens [13, 14] and affected the development of memory B lymphocytes and germinal centers [15]. In accordance with the proposed primary function of CD40/CD154 interaction, mutations in the ligand, interfering with receptor interactions, were identified as the cause of the X-linked immunodeficiency hyper IgM-syndrome (HIGM) [16], a disease associated with drastic or complete inhibition in the T cell-dependent humoral immune response.
Aside from the importance of CD154/CD40 interaction for appropriate immune responses, more recent studies have demonstrated a much broader expression pattern of both the ligand and its receptor, and associated CD154/CD40 interactions with diverse physiological and pathological processes: CD154, originally described on T helper cells, is also expressed on non-lymphoid cells, such as epithelial cells, monocytes, dendritic cells, fibroblasts, smooth muscle cells, and endothelial cells



Figure 1. Human cell types expressing CD40 and CD154.

Table 1.

Section	Title
1.	Introduction to the CD40/CD154 dyad
2.	Structure of CD154
2.1	Gene
2.2	Protein
2.3	Molecular structure
3.	Structure of CD40
3.1	Gene
3.2	Protein
3.3	Molecular structure
4.	Expression of CD154
4.1	Regulation of CD154 protein expression
4.2	Regulation of CD154 gene expression
4.3	Regulation of soluble CD154 expression
4.4	Cell types expressing CD154
4.4.1.	T lymphocytes
4.4.2.	Basophils
4.4.3.	Eosinophils
4.4.4.	Monocytes/macrophages, Kupffer cells
4.4.5.	Natural killer cells
4.4.6.	B lymphocytes
4.4.7.	Platelets
4.4.8.	Mast cells
4.4.9.	Dendritic cells
4.4.10.	Endothelial and smooth muscle cells
4.4.11.	Epithelial cells
5.	Expression of CD40
5.1	Regulation of CD40 protein expression
5.2.	Regulation of CD40 gene expression
5.3.	Cell type expressing CD40
5.3.1.	Hematopoeitic progenitor cells
5.3.2.	T lymphocytes
5.3.3.	Basophils
5.3.4.	Eosinophils
5.3.5.	Monocytes/macrophages
5.3.6.	Dendritic cells
5.3.7.	Epithelial cells
5.3.8.	Endothelial cells
5.3.9.	Smooth muscle cells
5.3.10.	Keratinocytes
5.3.11.	Fibroblasts
5.3.12.	Carcinomas
6.	CD40 signaling
6.1.	Activation of kinases/phosphatases
6.2.	CD40-binding proteins
6.3.	The role of STATs
6.4.	Transcription factors
7.	Biological function of the CD40/CD154 dyad
7.1.	T cell-dependent humoral immunity
7.1.1.	Activation of B lymphocytes
7.1.2.	Switching of immunoglobulin classes
7.1.3.	Formation of germinal center and memory cells
7.1.4.	Activation of lymphocytes via CD154
7.2.	Regulation of inflammatory mediators
7.2.1.	Cytokines
7.2.2.	Chemokines
7.2.3.	Adhesion molecules
7.2.4.	Extracellular matrix-degrading activities
7.2.5.	Procoagulant activities
7.2.6.	Other inflammatory mediators
7.3.	Apoptosis
8.	CD40/CD154 in human diseases
8.1.	Hyper-IgM syndrome
8.2.	Infectious disease
8.2.1.	Viral pathogens
8.2.2.	Intra-/extracellular microorganisms
8.3.	Transplantation
8.4.	Autoimmune disease
8.5.	Cardiovascular disease
8.6.	Cancer
8.7.	Other human diseases

[17–23]. Most of these ligand-bearing cells also express its counterpart CD40 [18–24]. The discovery of the broad distribution pattern of CD154 (see fig. 1) further implicated this receptor/ligand dyad in inflammatory and immune responses underlying various diseases, such as arthritis, cancer, atherosclerosis, lupus nephritis, and acute or chronic graft-versus-host disease.

To provide the reader with easy access to sections of interest, the review has been structured in divisions and subdivisions as outlined in table 1.

2. Structure of CD154

2.1. Gene

CD154, a type II transmembrance protein, belongs to the tumor necrosis factor (TNF) gene superfamily, consisting of molecules such as TNF, CD27 ligand, CD30 ligand, Fas ligand, lymphotoxin, and Ox40 ligand [25]. Human CD154 cDNA was obtained by screening activated peripheral blood T lymphocytes with the respective murine probe [8, 10, 11]. The 13-kb DNA sequence for CD154 shares 80% overall homology with its murine counterpart [26]. Mapped to chromosome X [10], region q26.3–q27.1, the gene is composed of five exons and four intervening introns [27], and encodes a 2.3-kb mRNA, which upon transcription yields a polypeptide consisting of 261 amino acids (260 amino acids for the murine ligand) (fig. 2). The large, 215 amino acid-long (214 amino acids for the murine ligand), cysteine-enriched (four cysteine residues) carboxy-terminal extracellular domain is mainly encoded by exons II–V, whereas the small transmembrane (24 amino acids) and amino-terminal intracellular (22 amino acids) domains are encoded by exon 1 [27, 28]. As characteristic for members of the TNF gene superfamily, the amino acid sequence of CD154 was suggested to align in the typical TNF-fold and bind to its receptor as a multimer [25, 29, 30], a hypothesis confirmed by recent studies, as described below.

2.2. Protein

Beside the cell-associated full-length 39-kDa protein, shorter soluble forms of the ligand have been described

with a molecular weight of 31, 18, and 14 kDa [31–33]. Recently, an additional 33-kDa CD154 species has been reported in murine B cells [33]. Further studies demonstrated that CD154 builds heteromultimeric complexes, consisting of full-length and/or smaller fragments, on the cell surface of human T lymphocytes [34]. The 18-kDa form, which lacks the cytoplasmic tail, the transmembrane region, and parts of the extracellular domain, is functional and is considered the soluble form of this 'cytokine' [32, 33]. However, the mechanism of solubilization remains unknown. Future studies will have to test whether the generation of soluble CD154 shows any analogy to the enzymatic cleavage pathway well characterized for other members of the TNF gene superfamily, such as FasL or TNF [35, 36].

2.3. Molecular structure

Despite the structural homology of the CD154 receptor-binding domain to other TNF gene superfamily members [37], considerable differences exist in several loops, including those predicted to be involved in CD40. In particular, neither the extracellular domain of CD154, which consists of a 75-amino acid spacer region immediately adjacent to the membrane-spanning region, nor the receptor-binding domain, consisting of two overlying β sheets as determined by the X-ray crystal structure, are shared with other TNF gene superfamily members [38]. The interaction between the receptor and its ligand is stabilized by charged residues, with CD154 presenting basic chains (K143, R203, R207) and CD40 presenting acidic side chains (D84, E114, E117) [39]. A wall of hydrophobic residues surrounds the polar interacting groups in the CD154/CD40 complex [39]. These studies extended earlier experiments that employed structure-based sequence alignments, side-directed mutagenesis, and receptor-ligand binding assays, demonstrating the importance of the CD154 residues K143, Y145, Y146, R203, and Q220, as well as the CD40 residues Y82, D84, E74, E117, and N86 for the binding process (probably by determining the structure of the protein, rather than by direct involvement in binding), indicating that CD154/CD40 interactions localize in two residue clusters [29, 30, 40]. Comparison of the CD154 and CD40 residues involved in the binding process with those residues identified in TNF-β/TNF receptor interactions demonstrated similarities but also unique features in the CD154/CD40 receptor ligand dyad. X-ray crystallographic and mutagenesis studies have suggested various models of human CD154 structure [37–41].

3. Structure of CD40

3.1. Gene

Bearing the type I extracellular binding motif and further structural homologies, CD40 is considered a member of



Figure 2. Organization of the human gene and protein for CD40 and CD154. Shown are the genomic (top) and protein (bottom) organization of CD40 (upper panel) or CD154 (lower panel). Exons are indicated as black boxes, labeled with the respective exon number.

the TNF receptor superfamily, encompassing the TNF receptor type I (p55-TNFR, CD120a), TNF receptor type II (p75-TNFR, CD120b), low-affinity nerve growth factor receptor, CD27, CD30, CD95 (Fas/Apo), Ox40, and 4-1BB [25]. Although the protein was identified on B lymphocytes by monoclonal antibodies in 1984 [1], another 5 years passed before the cDNA encoding CD40 was isolated from a mammalian expression library derived from Burkitt lymphoma Raji cell line revealing extensive homology with the nerve growth factor receptor [42]. The CD40 gene encodes a single 1.5-kb mRNA species and maps to human chromosome 20, bands q12–q13.2 [43, 44] and murine chromosome 2 [45]. Transcription of the gene results in a 277-amino acid membrane-bound protein that consists of a 22-amino acid signal sequence, a 171-amino acid extracellular domain, a single 22-amino acid transmembrane domain, and a 62-amino acid cytoplasmic domain (fig. 2). As typical for members of the TNF receptor superfamily, CD40 is characterized by a repetitive amino acid sequence pattern of four cysteine-enriched subdomains, typically consisting of six cysteines forming three disulfide domains. The intracellular domain of CD40, however, does not display a close relationship to other members of the family. The cytoplasmic domain of CD40 contains at least two major signaling determinants that include threonine 227 and 234, as discussed in detail below [46, 47]. Human and murine CD40 share 62% homology at the amino acid level throughout their open reading frames (78% for the intracellular domain, 100% for the C-terminal 32 residues). Activation of the murine gene results in two mRNA species (a. 1.4- and 1.7-kb form) by alternative usage of polyadenylation signals in the 3′ untranslated region, providing, however, identical coding sequences [48]. The 16.3-kb murine genomic DNA sequence for CD40 encodes nine exons [45].

3.2. Protein

Translation of the 1.5-kb CD40 mRNA generates an immunoreactive protein with a molecular weight of 43–50 kDa, mostly reported as a doublet consisting of a 43-kDa and a 47-kDa protein [4, 49]. Furthermore, dimer formation has been described in B lymphocytes [49]. Recent studies describing two CD40 epitopes that are differentially distributed on subpopulations of dendritic and epithelial cells indicate the possibility that this receptor might be expressed in a cell type-specific fashion [50].

3.3. Molecular structure

Relatively few experimental data exist regarding the molecular structure of CD40. Models of the receptor refer mostly to information obtained with the TNF receptor [51, 52], in which the 44-amino acid, six-cysteine residue, classical domain established the prototypical structure of this protein family. Indeed, several studies demonstrated that the domains involved in the interaction of CD40 with its ligand essentially correspond to those in the homologous TNF system, and a detailed three-dimensional model of the extracellular region of CD40 provided further evidence for structural homology with the TNF receptor [41]. Binding and mutagenesis analysis, X-ray crystallography, as well as molecular modeling experiments employing single and double amino acid-substituted proteins implicated the acidic side residues Y82, D84, E74, E117, and N86 in CD154 binding [29, 30], and further suggested that polar interactions in the surface of CD40, similar but inverted to those in the TNF receptor, stabilize the receptor-ligand complex [39].

4. Expression of CD154

4.1. Regulation of CD154 protein expression

Fusion proteins of the extracellular CD40 domain and the Fc region of human IgG1 have been employed to identify CD154 and to study the regulation of CD154 synthesis. Original studies demonstrated CD154 expression on activated mature but not resting human CD4+ T lymphocytes [8–12]. Within the T lymphocyte population CD154 is also found in Th0, Th1, Th2, CD8+, cells, as well as CD4−/CD8− δ T cell receptor (TCR)+ and $\alpha\beta$TCR+ T lymphocytes [53–56]. In accordance with this cellular distribution, immunhistochemical analysis demonstrated CD154+ T lymphocytes in the outer layers of germinal centers, the interfollicular T cell-rich areas, and the thymus [57, 58]. Although expression of CD154 is not restricted to T lymphocytes (as outlined below), our knowledge concerning the regulation of CD154 synthesis derives primarily from the original source. T lymphocytes can express CD154 on the cell surface as soon as 5 min after activation, indicating the ability to expose preformed CD154 [58]. The expression of the ligand on activated T lymphocytes, however, is transient, peaking 6 h after activation and declining over the following 12–24 h [54, 59]. Further studies established similar patterns of regulation on other CD154-expressing cell types, and revealed de novo synthesis of the protein following cell activation [18, 60]. The activation-induced expression of CD154 on T lymphocytes is regulated primarily by signaling through the TCR and might be enhanced by accessory molecules. However, these findings are controversial, since even in the absence of costimuli, CD154 expression in T lymphocytes is inducible by exposure to anti-CD3 or anti-CD2 antibodies [61, 62]. Accordingly

Roy et al. [63] further reported that the antigen-induced expression CD154 depends on TCR-derived signals, but not on CD28/CTLA-4 costimulatory signal. Further studies suggested that efficient expression of CD154 following polyclonal T lymphocyte activation requires accessory molecules on antigen-presenting cells (APCs), since costimulation of primary murine T cells via CD3 and CD28 can stabilize CD154 expression [64]. Thus, control of CD154 expression involves both costimuli-dependent and -independent pathways [65]. Other mediators of CD154 synthesis include: (i) ionomycin, which induces a very early mRNA and protein surface expression of CD154 within the first 2 h; (ii) the mitogens phytohemagglutinin and concanavalin A, which induce little CD154 itself, but together with PMA, yield markedly elevated CD154 expression [62]; (iii) formyl-methionyl-leucyl-phenylalanine (fMLP), and (iv) physiologically more relevant, proinflammatory cytokines, such as interleukin (IL)-1, TNF-α, and IL-4 [8, 12, 18, 53, 59, 66, 67]. Interestingly, elevated expression of CD154 also occurs after ligation of CD40 [60], indicating autologous regulation of this mediator. Interferon (IFN)-γ as well as transforming growth factor β (TGF-β) has been reported to inhibit CD154 mRNA expression in T lymphocytes [53, 54].

4.2. Regulation of CD154 gene expression

Few studies have addressed the mechanisms underlying CD154 gene expression. Activation of protein kinase C (PKC) and calcineurin, as well as a rise in intracellular calcium concentrations induce CD154 expression [62, 68], a finding supported by the recent demonstration that a calcium ionophore induces transcription of the CD154 gene in T lymphocytes, requiring the calcineurin-dependent transcription factor NF-AT [69]. Reporter gene assays using constructs driven by the promoter of human CD154 together with vectors expressing constitutively active calcium/calmodulin-dependent kinase IV, and calcineurin further revealed synergistic interactions between these two mediators. Finally, a dominant negative mutant of the calcium/calmodulin-dependent kinase IV shows diminished ionomycin-induced activity of the CD154 promoter as well as protein expression. Expression of CD154 can be inhibited by cyclosporin A [68]. Interestingly, patients who received cyclosporin A expressed peripheral blood T lymphocytes deficient in CD154 inducibility [68].

Early molecular characterization of the murine CD154 gene demonstrated a putative site for initiation of mRNA transcription 67 bp upstream of the translation initiation (ATG) codon, consisting of a TATA-like box, an Sp1-like box, and six potential NF-AT-like motifs [26]. Indeed, follow-up studies revealed four NF-AT-binding motifs in the CD154 promoter, consisting of two (cyclosporin A-inhibitable) complexes of NF-ATc and NF-ATp, and further demonstrated that NF-AT proteins are important for the expression of the CD154 gene, whereby transcriptional activity of NF-AT proteins requires AP-1 binding [70]. In addition, work by another group, sequencing a 1.2-kb fragment of the 5′ flanking region of the human CD154 gene promoter, identified two putative binding sites for the NF-AT family of transcriptional activator proteins at −259 bp to −265 bp and −62 bp to −69 with respect to the (cyclosporin A-inhibitable) transcriptional start site [71]. Both binding sites independently modulate CD154 promoter activity in response to T cell activation. Furthermore, two ATTTA elements were identified in the 3′ untranslated region of the murine CD154 gene, probably conferring post-transcriptional stability on the mRNA.

4.3. Regulation of soluble CD154 expression

Recently, soluble forms of CD154 have received more attention, particularly in association with certain human diseases, as reviewed in detail below. The first evidence that activated T lymphocytes not only express cell membrane-associated but also soluble CD154 emerged in 1995 [31]. The kinetics of soluble CD154 expression resemble those observed for the membrane-associated form, though the mechanisms of generation and/or release of soluble CD154 remain poorly understood. Several studies suggested that soluble CD154 is generated by intracellular proteolytic cleavage of the full-length form, producing an 18-kDa fragment starting at methionine 113 that lacks the transmembrane as well as parts of the extracellular domain, but conserves the CD40 ligation domain [31]. Consequently, sCD154 retains the ability to ligate CD40. Whether the proteolytic activity implicated in the formation of sCD154 involves mammalian adamalysins (AMAMs), which belong to the group of metalloproteinases [72], will require future experiments. However, the analogy of CD154 to TNF-α might suggest proteolytic pathways, resembling the function reported for the TNF-α-converting enzyme (TACE) [73, 74].

4.4. Cell types expressing CD154

As indicated above, the synthesis of CD154 was originally thought to be restricted to activated CD4+T lymphocytes, including cells of the Th0, Th1, and Th2 subtype [8–12]. However, succeeding studies demonstrated that further T lymphocyte subpopulations as well as other leukocytic and non-leukocytic cell types express CD154 (fig. 1). A common feature of the synthesis of CD154 in all cell types is the non-constitutive, inducible expression of this ligand, contrasting with the

mostly constitutive expression of its receptor, as described below.

4.4.1. T lymphocytes. Apart from CD4+ T lymphocytes, further subpopulations are capable of expressing CD154 mRNA and/or protein, including CD8+, CD45RO+/CD45RA+, or Tc1/Tc2 T lymphocyte subsets [53–55, 75, 76], as well as CD4/CD8-negative T lymphocytes [56]. Inducibility of CD154 expression on T lymphocytes seems to depend on maturation, since immature thymocytes do not express CD154 on their surface after stimulation, indicating acquisition of the ability to express the ligand late in thymocyte development [77]. Accordingly, umbilical cord peripheral blood CD4+ T lymphocytes express little or no CD154 upon activation [78].

4.4.2. Basophils. Freshly isolated purified human peripheral blood basophils as well as the human basophilic cell line KU812 express (upon activation) functional CD154, capable of inducing IgE production, suggesting that basophils might play an important role during allergy, not only by producing inflammatory mediators, but also by directly regulating IgE production independently of T lymphocytes [79, 80]. Those findings have been confirmed with umbilical cord basophilic cells [81].

4.4.3. Eosinophils. Peripheral blood eosinophils as well as the eosinophilic cell line EOL-3 express functional CD154 upon activation, whereas eosinophils from hypereosinophilic patients express CD154 constitutively, indicating a role for CD154 in the inflammatory processes involving eosinophil infiltration and activation [82]. Presentation of CD154 at the surface of eosinophils mediates proliferative signals on CD40-positive target cells, such as Reed-Sternberg cells, demonstrating its functionality.

4.4.4. Monocytes/macrophages and Kupffer cells. Initial observations in mononuclear phagocytes revealed CD154 mRNA within monocytes extracted from human peripheral blood [83]. More recent studies demonstrated the inducibility of CD154 mRNA and biologically functional protein in human peripheral blood monocytes in vitro by cytokines, such as IL-1 or TNF-α, and enhanced expression of the ligand on activated monocytes in situ within human atherosclerotic lesions [18] as well as during chronic allograft rejection in human liver allografts [84, 85].

4.4.5. Natural killer cells. Natural killer (NK) cells contain CD154 transcripts [83] and show enhanced CD154 expression upon stimulation with IL-2. The ligand is functional as demonstrated by the killing capability of CD154-positive, but not CD154-deficient, NK cells [86]. These studies suggested a potential role for CD154 in NK cells in immune responses against B cell malignancies.

4.4.6. B lymphocytes. Purified human peripheral blood B lymphocytes, as well as a variety of B lymphoblastoid cell lines and hybridomas can express functional CD154 following activation, which gave rise to the presumption that this mediator might facilitate responses of activated B lymphocytes [87, 88]. Interestingly, B lymphocytes of patients with active systemic lupus erythematosus or hematological malignancies spontaneously express levels of CD154 comparable to those found in T lymphocytes [88–90]. These studies further reported that malignant B lymphocytes coexpressed CD40 and CD154 protein. In vivo studies demonstrated constitutive CD154 expression on peripheral blood B cells in mice, augmented upon endotoxin stimulation [91]. However, mouse B lymphocytes seem to express CD154 in the cytoplasm rather than on the surface, but readily release the mediator as a soluble molecule upon stimulation with anti-Ig antibodies or CD154 itself [33].

In addition, recent studies have established that non-leukocytic cells can also synthesize functional CD154, as described below.

4.4.7. Platelets. Recently, thrombocytes were identified as another source of CD154 [92]. Expression of the ligand was observed only seconds after activation of the platelets in vitro and in the process of thrombus formation in vivo. Further studies demonstrated the biological functionality of the ligand, since it induces expression of chemokines, adhesion molecules, and tissue factor, and diminishes the expression of thrombomodulin in human vascular endothelial cells [93].

4.4.8. Mast cells. The human mast cell line HMC-1, freshly isolated purified human lung mast cells, as well as nasal mast cell from patients with perennial allergic rhinitis express functional CD154 in vitro and in situ [79, 94].

4.4.9. Dendritic cells. Human blood dendritic cells express constitutive CD154 mRNA and protein [60]. Interestingly, ligation of CD40 induces expression of the CD154 gene leading to a rise in ligand levels on the dendritic cell surface [60]. Dendritic cell CD154 is functional, as demonstrated by the finding that CD154-deprived dendritic cells lose their capability to regulate B cell activation and maturation [60]. Lung dendritic cells in mice also express CD154 [95].

4.4.10. Endothelial and smooth muscle cells. Human vascular endothelial and smooth muscle cells express functional CD154 in vitro and at sites of inflammation, e.g., atherosclerotic lesions as well as rejected cardiac and renal allograft transplants, in situ [18, 84, 96, 97]. Cultured endothelial and smooth muscle cells express little constitutive CD154, but show marked increases 12–24 h after stimulation with IL-1, TNF-α, IL-4, or IFN-γ [18, 96].

4.4.11. Epithelial cells. CD154 expression is induced on glomerular and tubular epithelial cells during human

chronic renal allograft rejection [97], but seems to be absent on normal human bronchial epithelial cells [98].

5. Expression of CD40

5.1. Regulation of CD40 protein expression

CD40 was originally described by independent groups who identified an approximately 50-kDa polypeptide on the surface of B lymphocytes or carcinoma cells [1–4]. Signaling via this receptor stimulates the transition of B lymphocytes through the cell cycle, affecting B cell proliferation and DNA synthesis, functions resembling those of a growth factor receptor [99–101]. Originally termed p50 or Bp50 [3, 4], this molecule was initially designated as CDw40 and finally, in 1989, as CD40. This phosphoprotein is characterized by Western blot analysis as three immunoreactive proteins: a main band of 47 kDa, a degradation product of 43 kDa, and a dimer of 85 kDa. Although constitutively expressed on most cell types, expression of the CD40 protein can be regulated. Stimuli for CD40 expression include cytokines, such as IFN-γ, IL-1, IL-3, IL-4, TNF-α [19, 42, 98, 100–105], granulocyte/macrophage colony-stimulating factor (GM-CSF) [105], human immunodeficiency virus (HIV) [106], Epstein-Barr virus latent membrane protein (LMP-1) [107], phorbol esters [108], *Mycobacterium tuberculosis* bacilli [109], 12-O-tetradecanoyl phorbol-13-acetate (TPA) [99], antibodies against IgM or CD20 [99], as well as ultraviolet (UV) light exposure [110]. Induced expression of CD40 is typically observed 6–12 h following stimulation, peaks after 24 h, and persists for an additional 24–72 h, in contrast to the transient expression of its counterpart, CD154.

5.2. Regulation of CD40 gene expression

Very few studies have analyzed the mechanisms underlying CD40 gene activation. Though the CD40 promoter structure is unknown, inducibility of CD40 expression via IFN-γ in most cell types analyzed suggested the presence of signal transducer and activator of transcription (STAT) sites. Indeed, in vascular smooth muscle cells, activation of the CD40 gene via this cytokine is mediated via STAT-1 [111]. Interestingly, CD40 gene expression in these cells via TNF-α is mediated via a different transcription factor, NF-κB [111]. Craxton et al. [112] further demonstrated that potential autocrine induction of CD40 via CD40 ligation does not depend on p38 mitogen-activated protein kinase (MAPK), a mediator of other CD40-mediated functions. These studies further revealed that induction of CD40 expression via proinflammatory cytokines is regulated at the transcriptional level and requires ongoing protein synthesis [113]. Interestingly, inhibition of CD40 expression by certain cytokines, such as TGF-β, occurs via enhanced degradation of CD40 mRNA rather than directly at the transcriptional level [113]

5.3. Cell types expressing CD40

Detailed studies performed with the original source of CD40 showed expression during early B cell development. Embryogenic B lymphocytes already express CD40 [108, 114, 115], consistent with a functional role for CD40 in B cell ontogeny [116, 117]. In addition to its role in early ontogeny, nearly every human adult B lymphocyte expresses CD40 regardless of its function (naïve cell, centroblast, plasmablast, plasma cell, memory cell) or location (bone marrow, tonsil, spleen, primary/secondary follicle) [as reviewed extensively elsewhere see refs 28, 118, 119]. Furthermore, most malignant/leukemic B cell lines express CD40 independently of the degree of maturation of the affected lineage [3, 99, 108, 115, 120–123]. In addition to the cell-associated form of CD40, tonsillar B lymphocytes and transformed B cell lines can release soluble CD40, which binds to CD154 on T lymphocytes [124, 125], implicating sCD40 in the modulation of T cell stimulation. Other leukocytes capable of expressing CD40 are detailed below.

5.3.1. Hematopoetic progenitor cells. Knowledge regarding CD40 expression on progenitor cells is restricted mostly to the B lymphocyte lineage. Acquisition of the CD40 antigen in human B lymphocyte ontogeny occurs subsequent to the expression of CD10 and CD19 antigens but precedes the surface expression of CD20, CD21, CD22, CD24, surface immunoglobulin M (sIgM), and the rearrangement of Ig heavy-chain genes [115, 126]. Analysis of human CD34+ bone marrow and umbilical cord blood cells also showed transient expression of CD40 early in myeloid development [114]. Several studies demonstrated that dendritic Langerhans, CD34+ progenitor cells derived from cord blood actually express functional CD40 at a density higher than that found on B lymphocytes [21, 127]. In addition, CD40-activated cord blood CD34+ progenitors proliferate and differentiate into cells with prominent dendritic cell attributes, such as priming of allogeneic naïve T lymphocytes, indicating that CD40 ligation generates dendritic cells that may prime immune reactions during antigen-driven responses to pathogenic invasion, thus providing a link between hematopoiesis, innate, and adaptive immunity [128].

5.3.2. T lymphocytes. Originally discovered on T lymphocytes of various body compartments of rheumatoid arthritis patients [129], expression of CD40 transcripts and protein localizes to activated CD4+, CD8+, and $CD4^{+}/CD8^{+}$ T cell clones as well as TCR+ T lymphocytes [130, 131]. Follow-up studies

revealed functionality of this receptor, since ligation by CD154 induces CD25 and CD154 expression on resting peripheral blood T lymphocytes, CD69 expression on CD3-activated cells, proliferation of activated CD4+ and CD8+ T lymphocytes, and secretion of IFN-γ, TNF-α, and IL-2, implicating CD154 in T lymphocyte activation [132, 133].

5.3.3. Basophils. Basophils enriched from chronic myeloid leukemia blood and dispersed lung tissue as well as human basophil-like cell lines react with antibodies directed against CD40 [134, 135]. This cell type expresses CD40 protein early during differentiation [136].

5.3.4. Eosinophils. Human peripheral blood eosinophils and activated eosinophils from atopic patients express elevated levels of CD40 transcripts and protein. CD40 expressed on eosinophils is functional, as ligation of the receptor enhances eosinophil survival and induces the release of GM-CSF [137]. In vitro CD40 expression in eosinophils is augmented by IgA immune complexes and reduced by IL-10 [137].

5.3.5. Monocytes/macrophages. Primary human peripheral blood monocytes and the monocytic cell line U937 express CD40 mRNA and CD40 cell surface protein following treatment with GM-CSF, IL-3, IFN-γ, or soluble CD23 [23, 138]. In accordance with other leukocytic cell populations, monocytes express CD40 constitutively. Interaction of CD40/CD154 provides a critical trigger for the CD4+ T cell contact-dependent activation of monocytes [139–143]. This interaction might be bidirectional, because the resulting phenotypic changes on monocytes may mediate T cell activation, thus enhancing and/or prolonging inflammatory responses [144]. Furthermore ligation of CD40 on monocytes/macrophages induces IL-12 expression [141, 145], which can in turn induce CD154 expression on the T lymphocyte [146]. Interestingly, disturbed CD40 expression and signaling patterns have been reported for monocytes/macrophages within UV light-exposed skin [147] as well as within the peripheral blood of HIV-1-positive patients [148].

5.3.6. Dendritic cells. Enrichment of human peripheral blood [149], tonsil [150], or dermal dendritic cells [151, 152] revealed the capability of this cell type to express CD40. Ligation of CD40 on human cord blood-derived CD34+ hematopoietic progenitors [128, 153] as well as CD68+ blood cells [154], or adherent peripheral blood monocytes [155] induced their proliferation as well as differentiation into functional dendritic cells, demonstrating functionality of the receptor. CD40 activation induced dendrite development, alterations in the phenotype, as well as elevated expression of MHC class II antigens, CD25, CD58, CD80 (B7-1), CD86 (B7-2), and CD154, cytokines, such as TNF-α, IL-8, IL-10, and IL-12, and chemoattractants, such as macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES [21, 60]. Several groups provided evidence for the potential importance of CD40/CD40 ligand-dependent T lymphocyte-dendritic cell interaction, e.g., for the functional development of B cell follicles and adaptive immune responses [105, 156–160; also reviewed in refs 161, 162]. In particular, the role of CD40 ligation for the induction of IL-12 expression has been the focus of several studies. Originally, ligation of the receptor was considered sufficient to induce expression of the cytokine. However, further studies suggested that induction of IL-12 p40 and p75 expression in dendritic cells, via antigen-specific Th1 lymphocytes, which do not differ in either TCR clonotype or CD154 expression, requires IFN-γ as a second signal [163, 164]. Accordingly, Th2 class lymphocytes do not induce, but interestingly inhibit the expression of IL-12. In situ, elevated expression of CD40 has been reported in dendritic cells within non-Hodgkin's lymphomas [165, 166] as well as rheumatoid synovial fluid and synovial tissue [167].

In addition, non-leukocytic cells can also express CD40 (fig. 1).

5.3.7. Epithelial cells. Immunohistochemical analysis revealed CD40 expression on epithelial cells of human nasopharynx, tonsil, and ectocervical tissue, as well as cultured epithelial cells and several epithelial cell lines [168]. The presence of CD40 on diseased and its absence on unaffected epithelium as well as its inducibility by proinflammatory cytokines, e.g., IFN-γ, indicated a role for epithelial CD40 in the development of carcinomas/epithelial neoplasia at sites of chronic inflammation [42], a hypothesis also supported by the later finding that a large majority of nasopharyngeal carcinoma cells expressed CD40 [169]. Further studies of CD40 distribution in the human thymus revealed that cortical and medullar thymic epithelial cells express this receptor in situ and, inducible via proinflammatory cytokines, e.g., IL-1, TNF-α, or IFN-γ, also in vitro [19, 170]. Further studies demonstrated that CD40 expressed on these thymic epithelial cells provides costimulation for clonal expansion of CD4+ thymocytes [17]. In addition to neoplastic and thymic epithelial cells, normal human bronchial epithelial cells constitutively express CD40 in situ [98]. Interestingly, as in the case of dendritic cells, murine epithelial cells are suggested to express different isoforms of CD40 [50].

5.3.8. Endothelial cells. Three different groups independently described in situ and in vitro expression of CD40 on human endothelial cells [20, 22, 24]. All studies demonstrated constitutive basal expression of CD40, which augmented after stimulation with proinflammatory cytokines, such as IL-1, TNF-α, or IFN-γ. Interestingly, a combination of IFN-γ with either IL-1 or

TNF-α acted synergistically, indicating independent pathways for the induction of CD40 gene expression. The receptor on endothelial cells is functional, since CD40 ligation induces expression of adhesion molecules, such as E-selectin, vascular cell adhesion molecule (VCAM)-1, or ICAM-1. Immunohistochemical analysis localized CD40 on endothelial cells of the normal human spleen, thyroid, skin, muscle, kidney, lung, blood vessels, and umbilical cord [20, 22, 24, 172]. However, endothelial cells of tissue involved in inflammatory disease, benign tumors of vascular origin, renal carcinomas, and Kaposi's sarcoma were also demonstrated to express elevated CD40 compared to undiseased tissue [20, 172–174], supporting the hypothesis that this surface receptor plays an important role in tissue inflammation. Further studies revealed that other inflammatory diseases such as allograft rejection [96], atherosclerosis [18, 175], lupus glomerulonephritis [176], HIV infection [106], and probably Alzheimer's disease [177] are associated with elevated expression of endothelial CD40.

5.3.9 Smooth muscle cells. CD40 expression on smooth muscle cells was first described within the atherosclerotic vessel wall [18]. Further studies also demonstrated CD40 expression on cultured smooth muscle cells of the human airways [178]. Both studies showed that CD40 expression on smooth muscle cells is upregulated in vitro upon stimulation with proinflammatory cytokines, e.g., IL-1, TNF-α, or IFN-γ, and that CD40 is functional on these cells [18, 179, 180].

5.3.10. Keratinocytes. Initial studies reported that epidermal keratinocytes express low levels of CD40 in vitro, and had enhanced levels after stimulation with cytokines such as IFN-γ [181]. Later studies demonstrated that undifferentiated and terminally differentiated human keratinocytes express CD40 transcripts as well as protein constitutively [182–184]. The receptor is functional, since ligation induces expression of cytokines, adhesion molecules, and reduces keratinocyte proliferation. Markedly elevated levels of CD40 expression in situ have been reported for the proliferative layers of benign viral-induced cutaneous lesions [185] and in psoriasis, a T cell-mediated inflammatory skin disease [183].

5.3.11. Fibroblasts. Expression of CD40 on human fibroblasts was originally reported by several groups [104, 186, 187], who described CD40 transcripts and protein on human lung, gingival, synovial, dermal, and spleen fibroblasts, as well as on cultured human fibroblasts. Later studies added rheumatoid synovium [188], thyroid fibroblasts in culture [189], orbital connective tissue fibroblasts obtained from normal donors and from patients with severe thyroid-associated ophthalmopathy [190], as well as periodontal ligament and orbital connective tissue fibroblasts [190, 191] to the list of origins. The expression of CD40 mRNA and protein in fibroblasts is induced by proinflammatory cytokines, e.g., IFN-γ [186, 188, 189]. CD40 expressed on fibroblasts is functional and ligation induced expression of adhesion molecules, cytokines, cyclooxygenase-2, and prostaglandin E_2 [104, 192, 193], and inhibited the expression of matrix metalloproteinases (MMPs), such as MMP-1 and MMP-3, in these cells [194]. Furthermore, CD40 expression relates to cell growth, because (i) in vitro confluent fibroblast cultures express higher levels of the receptor than fibroblast in log phase and (ii) ligation of CD40 induces fibroblast proliferation [104, 186]. Further studies suggested that CD40-mediated cognate interactions between tissue fibroblasts and infiltrating T lymphocytes promote fibrogenesis [195].

5.3.12. Carcinomas. Early evidence for overexpression of CD40 in Hodgkin's disease emerged from immunohistochemical analysis [196]. CD40 is strongly expressed with a highly distinct pattern of staining on Reed-Sternberg cells, the presumed malignant cells of Hodgkin's disease, and variants of Hodgkin's disease, irrespective of their antigenic phenotype (T, B, non-T-non-B) or histologic subtype [197–199]. Furthermore, primary and cultured Hodgkin's and Reed-Sternberg cells express high levels of CD40. Functionality of the receptor on these cells was demonstrated by induction of cytokines and adhesion molecules after ligation of the receptor on cultured Hodgkin's and Reed-Sternberg cells [199, 200]. Other, non-lymphoid carcinoma tissue can also express CD40, including epidermal tumors, cutaneous malignant melanoma, osteosarcoma, breast carcinoma, or cervical carcinoma, in which either epithelial cells, endothelial cells, or keratinocytes can express CD40 [169, 172, 185, 201–205].

6. CD40 signaling

Despite the impressive amount of data garnered within recent years, our knowledge regarding CD40-mediated signal transduction pathways and associated transducers remains incomplete and controversial. The controversies result, in part, from differences in CD40-mediated signal transduction among cell types and, furthermore, can vary within the same cell type depending on the stage of differentiation, as previously discussed elsewhere [206]. Most of the signaling studies have employed B lymphocytes, where the analysis of primary cells versus cell lines provided an additional source for controversiality. These considerations should be borne in mind during the following review of the literature analyzing the CD40-mediated signaling pathways.

Based on the structural homologies with the TNF/TNF receptor family, CD154 had been predicted to form trimeric structures, which as a consequence of receptor-ligand interaction results in the trimerization of CD40



Figure 3. Potential mechanisms of CD40 signaling. Shown are potential extracellular (*A*) and intracellular (*B*) processes occurring during CD40 signaling involving the respective members of the TRAF family. (*C*) Prototypical organization of TRAF proteins.

receptor proteins [37] (fig. 3A). Indeed, CD154 and subsequent CD40 oligomerization are crucial steps in CD40-mediated signal transduction; hence, trimeric CD154 molecules exhibit the higher potency compared to monomeric or dimeric forms [207].
Initial studies on CD40 signaling focused on the phosphorylation of the receptor itself [101, 208]. CD40 contains at least two major signaling determinants in the cytoplasmic domain, one of which includes threonine 234 [46]. Substitution of an Ala for this Thr at position 234 as well as deletion mutants lacking Thr234 inhibit signal transduction after CD40 ligation [209]. Furthermore, these phosphorylation sites reside within areas of the cytoplasmic domain deemed critical for signal transduction because of association with CD40-binding proteins [210], as discussed below. These findings, in combination with the lack of intrinsic protein kinase activities [10] of the receptor, suggested the following events in CD40-mediated signal transduction: (i) activation of separate kinases/phosphatases and/or (ii) association of regions of the cytoplasmic domain with binding proteins. As discussed in detail below, both mechanisms probably contribute to the CD40-signaling pathway.

6.1. Activation of kinases/phosphatases

Most studies implicate activation of protein tyrosine kinases and protein tyrosine phosphatases as immediate intracellular responses during CD40 activation. Initial studies demonstrated that ligation of CD40 on activated, but not on resting mature B lymphocytes enhanced tyrosine phosphorylation of four distinct phosphoproteins with molecular masses of 67, 72, 96, and 113 kDa, and induced a rapid increase in the production of inositol 1,4,5-trisphosphate [211]. The same study further identified five electrophoretically distinct renaturable, CD40-regulated serine/threonine-specific protein kinases (PK120, PK93, PK76, PK55, and PK48) that showed markedly increased in vitro activity after CD40 stimulation. Furthermore, CD40 ligation causes phosphorylation of phospholipase $C\gamma 2$, and the 85-kDa, but not the 110-kDa, subunit of the phosphatidylinositol-3-kinase, increasing their activity, and suggesting a role for these two enzymes in CD40 signal transduction [212]. These findings agree with later reports describing rapid induction of a wortmannin (or similar inhibitor)-sensitive kinase activity, probably phosphatidylinositol-3-kinase, following CD40 ligation [213]. Furthermore, the finding that stimulation of Daudi B cells with an activating anti-CD40 antibody stimulates p21ras, in parallel with tyrosine phosphorylation of phosphatidylinositol 3-kinase and stimulation of Rac1 and MEK-1 [214], implicated participation of the Ras pathway in CD40 signaling.
Whether CD40-mediated signal transduction pathways involve PKA, e.g., during B cell activation, remains controversial [215–217]. Cyclic AMP can increase following CD40 ligation and regulate CD40 signaling either positively or negatively [216, 217]. The role of PKC in CD40 signaling seems restricted to downstream rather than immediate signaling events [211, 212, 218–223]. Ligation of CD40, for example, transiently activates stress-activated protein kinases (SAPK) via PKC-independent pathways [224]. Some studies reported that CD40 ligation does not affect members of the MAPK family, e.g., extracellular signal-regulated protein kinase (ERK)-1 and ERK-2, while others describe involvement of the ERK cascade, in particular ERK-2, in CD40 signaling in a mouse B cell lymphoma cell line [225, 226]. Other studies report that CD40 engagement enhances ERK activities [227, 228]. Again, these disparate results may reflect use of cells of different origin as also indicated by a recent study demonstrating that CD40 ligation induces ERK activation in normal B lymphocytes, but not or only weakly in B lymphocyte lymphoma cells (WEHI-231) [215]. In monocytes, ligation of CD40 resulted in the phosphorylation and activation of ERK-1 and ERK-2, but not phosphorylation of other MAPK family members, such as p38 or c-Jun N-terminal kinase [229].
Studies in which protein tyrosine kinase inhibitors, such as herbimycin, block aggregation as well as rescue of germinal B lymphocytes, indicated the potential importance of protein tyrosine kinases in the pathway of CD40 signaling [230, 231]. In particular, the Src family tyrosine kinases, syk, lyn, and fyk, have been associated with CD40 signaling [212, 232]. Ligation of CD40 finally also induces alterations in the state of tyrosine phosphorylation of CD45, a protein tyrosine phosphatase [232].

6.2. CD40-binding proteins

Since direct association of the respective kinases/phosphatases with CD40 could not be demonstrated, the association of intermediary CD40-binding proteins has been considered crucial in CD40-mediated signal transduction, possibly ultimately mediating the more downstream function of those non-receptor kinases/phosphatases described above. In 1994, a member of the family TNF receptor-associated proteins, TRAF-3, was identified as the first protein associated with the cytoplasmic domain of CD40. Originally, this ubiquitously expressed 62-kDa intracellular protein had been termed CD40-binding protein [210], CRAF1 [CD40-receptor associated factor 1; 233], LAP1 [LMP-1-associated protein 1; 234], or CAP1 [CD40-associated protein 1; 235]. A direct role for TRAF-3 in CD40 signaling was postulated after the demonstration that the growth

transformation of B lymphocytes by Epstein-Barr virus is mediated through the interaction of the carboxy-terminal 44 amino acids of the virus latent infection membrane protein 1 (LMP-1), which contains various TRAF-binding sites [234, 236]. TRAF-3, located on chromosome 14, band q32.3, is encoded by a single gene comprised of 13 exons, spanning 130 kb, that generates a variety of mRNA species by alternative polyadenylation, mRNA splicing, and transcription initiation [237]. TRAF-3 interacts directly with the cytoplasmic tail of CD40 through a region termed the TRAF domain [209, 233, 235]. This domain is required for association with the cytoplasmic domain of the related 75-kDa TNF receptor and can form homo- and heterodimers.

The TRAF family consists of six known members (TRAF-1 to TRAF-6) that share homology in the C-terminal TRAF domain, required for multimerization and binding to members of the TNF receptor family (see also fig. 3). Following TRAF-3, another member of the family, TRAF-2, has been shown to bind to the cytoplasmic domain of CD40 [238]. Recent data indicate that the association with CD40 might be regulated via the phosphorylation status of TRAF-2 [239]. In addition to the CD40-binding domain, both TRAF members share several other functional domains: the N-terminal portion of TRAF-3 and TRAF-2 contains a RING finger motif and five zinc finger-like domains similar to those found in DNA-binding proteins [210, 233, 235, 238]. Based on the structural similarities within the putative DNA-binding domains, TRAFs have been speculated to function as direct transcriptional regulators [206]. DNA binding of the CD40-associated factors would require release from the receptor. Even though CD40 and TRAF-2 were found constitutively associated with each other, ligation of CD40 itself seems to inhibit the binding of TRAF-2 to the CD40 cytoplasmic domain [240]. However, final evidence for a direct path from CD40 ligation to DNA regulatory functions via TRAFs remains to be demonstrated. Moreover, binding of TRAFs via their conserved TRAF domain to the respective receptor might be further regulated by TRAF-interacting protein(s), endogenous inhibitors of TRAF functions, such as the recently described I-TRAF, which inhibits TRAF-2-mediated NF-κB activation signaled by CD40 [241].

Following TRAF-2 and TRAF-3, further members of the TRAF family, TRAF-5 and TRAF-6, have been associated with CD40 signaling [242, 243]. Both TRAF-5 and TRAF-6 contain the characteristic carboxy-terminal TRAF domain and the amino-terminal RING finger domain as well as a cluster of zinc fingers. Overexpression of TRAF-5 and TRAF-6, in contrast to TRAF-3, activates NF-κB. TRAF-6, which associates with CD40, but interestingly not with the cytoplasmic tails of TNF receptor type 2 [243, 244], further activates ERK [227], indicating only one of several possible links to the kinase/phosphatase pathways described above. Whether TRAF-5 associates with the cytoplasmic tail of CD40, as suggested by Ishida et al. [242] is controversial, since other groups demonstrated that TRAF-5 binds to the cytoplasmic region of the lymphotoxin-β receptor, but not to most nerve growth factor receptor family members, including CD40 [244, 245].

Using peptides with progressive deletions, the PVQET as well as the QEPQEINF sequence within the CD40 cytoplasmic domain were mapped as the minimal TRAF-1-, TRAF-2-, and TRAF-3-, as well as TRAF-6-binding region, respectively, indicating that the CD40 cytoplasmic domain contains two non-overlapping TRAF-binding regions, associated with residues 203–245 and residues 246–269, respectively (fig. 2) [242–244]. Interestingly, the TRAF domains of TRAF-1, TRAF-2, TRAF-3, and TRAF-6 formed homotrimers in solution, suggesting that TRAF trimerization is required for high-affinity interactions with CD40 [246]. Accordingly, monomeric TRAF-C domains bind less potently to CD40 than trimeric TRAFs. With respect to binding affinities, trimeric TRAF-2 was stronger than that of TRAF-3. Although TRAF-1 and TRAF-6 also bind to CD40, their affinities were found to be much less. The composition of TRAFs within a cell probably varies with the activation status, since CD40 ligation on B lymphocytes recruits TRAF-2 and TRAF-3 to the receptor, while suppressing other, non-receptor-associated TRAFs.

In summary, the following scenario emerges from these data: binding of the trimeric ligand causes trimerization of CD40, a process that presumably allows the trimeric association of members of the TRAF family, particularly TRAF-2 and TRAF-3, and probably less efficiently TRAF-1 and TRAF-6 (as well as probably TRAF-5 via association with TRAF-3) with the receptor (as summarized in fig. 3A,B). Depending on the cell type, certain TRAF members might preferentially associate with the CD40 cytoplasmic domain and mediate downregulation of other, non-associated TRAFs. These CD40-binding proteins finally, directly and/or indirectly, might regulate gene transcription, probably in part via activation of NF-κB or AP-1.

The hypothesis that TRAF proteins couple CD40 to the kinase cascade, which finally might activate NF-κB, JNK, and/or p38 MAPK, receives further support from the demonstration that the cytoplasmic domain sequence, which is required for the binding of TRAF-1, TRAF-2, and TRAF-3/TRAF-5, constitutes an independent signaling motif, reported sufficient for the activation of JNK and p38 MAPK pathways, as well as for IκBα phosphorylation and degradation [247]. The hypothesis of coexisting direct and indirect TRAF-medi-

ated gene transcription is also supported by the demonstration that different TRAFs as well as different domains of the respective TRAFs might mediate NF-κB and JNK signaling differentially [248–250]. TRAF-2, TRAF-5, and TRAF-6 effectively initiate NF-κB activation (a function that requires an intact zinc ring finger) as well as the JNK pathway, whereas TRAF-3 initiates independent signaling pathways via p38 and JNK, but does not affect NF-κB activity. Furthermore, different TRAF family members might activate the same transcription factor, e.g., NF-κB, by separate pathways [250]. In accordance with this finding, Kehry's group demonstrated that optimal NF-κB and JNK activation requires both TRAF-1/TRAF-2/TRAF-3- and TRAF-6-binding sites, whereas p38 MAPK activation depends primarily on TRAF-6. These results suggest a role in CD40 signaling for competitive TRAF binding and imply that CD40 responses reflect an integration of signals from individual TRAFs [251]. Furthermore, evidence has been provided that different target genes might be regulated via different TRAF family members. CD40 mutants incapable of binding certain TRAF members demonstrated that TRAF-2 rather than TRAF-3 is critical for the gene transcription of ICAM-1, which is probably NF-κB mediated [252]. These findings agree with the earlier association of TRAF-2 rather than TRAF-3 with NF-κB-mediated gene activation [238].

The involvement of other proteins in CD40 signaling remains to be determined. Recently, a novel 61-kDa serine/threonine kinase has been identified as part of the CD40 signaling complex, and termed receptor-interacting protein 2 (RIP-2); it interacts with TRAF-1, TRAF-5, and TRAF-6, but not with TRAF-2, TRAF-3, or TRAF-4 [253]. Furthermore, a recently identified member of the TNF receptor superfamily termed receptor activator of NF-κB (RANK) contains two distinct domains in the cytoplasmic tail that provide multiple TRAF-binding sites, mediating the association with TRAF-1, TRAF-2, TRAF-3, TRAF-5, and TRAF-6, as well as the induction of NF-κB, AP-1, and c-Jun NH_2-terminal kinase activities [254].

6.3. The role of STATs

Besides TRAFs, members of the STAT family were originally associated with CD40 signaling, probably via mechanisms resembling those described above for the TRAF pathway. STAT proteins, which become phosphorylated by kinases of the Jak family after ligation of the IFN-γ receptor, assemble into complexes, translocate to the nucleus, and bind specific DNA elements, enabling them to direct transcription [255]. In accordance with this hypothesis, CD40 engagement on murine B cells results in rapid tyrosine phosphorylation of the STAT-6 transcription factor, transactivation of a reporter gene containing an IFN-regulatory factor-1 STAT-binding site [256], and the expression of members of the Janus family of protein tyrosine kinases, such as Jak-3 [257]. However, recent studies suggested that, at least within B lymphocytes, JAK-3 is not essential for CD40 signaling [258]. Hence, the role of STAT-6 in CD40 signaling remains unclear, since mutation of a STAT-6-binding site in B lymphocytes did not affect transcription of the lymphotoxin α gene driven by stimulation with an anti-CD40 antibody [259]. Other studies demonstrated that ligation of CD40 indeed induces STAT-6, but further demonstrated that a STAT-6-binding site might not be required for the transcription of target genes [260].

6.4. Transcription factors

Regarding the transcription factors involved in CD40-mediated signaling, early studies already demonstrated that ligation of CD40 activates NF-κB and NF-κB-like transcription factors, including the NF-κB family members p50, relA, and c-Rel [218, 261, 262]. Kosaka et al. [263] recently showed that ligation of CD40 results in the activation of IκB kinase in a human B cell line, and furthermore established a functional link between TRAF-2 and IκB kinase activity. CD40 ligation has also been suggested to induce NF-κB expression via the PI3-kinase pathway [219]. Recent studies in WEHI cells demonstrated that a 17-amino acid sequence within the cytoplasmic domain, termed CD40 TNF-associated factor family member-interacting motif (TIM), confers NF-κB activability [264]. CD40-mediated NF-κB activation might require IL-4 as a cofactor, at least in certain cell types [265].

Aside from NF-κB, CD40 ligation results in the activation of the inducible transcription factor complex, AP-1 [218], typically consisting of heterodimers between Jun and Fos proteins, a finding consistent with the description of CD40-induced expression of JunB, JunD, and c-Fos in primary B lymphocytes [266]. However, these data conflict with results of another study describing CD40 signal upregulation of c-jun but not c-fos mRNA in primary B lymphocytes as well as B cell lines [224]. The latter study also provided evidence that CD40 signals alter the transcription factor ATF2 but not the Raf-1 protein. Furthermore, ligation of CD40 induces activation of NF-AT in humans [218, 267] as well as in mice [268], and modulates E2F activity in B cell lymphoma [269]. The CD40-dependent activation of these members is rapid, and evidence has been provided that it is mediated through a tyrosine kinase- and TRAF-dependent pathway [262]. Reactive oxygen intermediates have also been suggested to act as second messengers during CD40 signaling [270].

Furthermore, some evidence supports convergence of the signaling pathways for CD40 and the B cell receptor. It remains to be determined, however, whether this occurs within the cytosol and is mediated via kinases, such as those of the Src kinase family [206], or the MAPK kinase, MEK-1 [215], or within the nucleus, mediated via respective transcription factors [218].

The studies reviewed above address mainly CD40 signaling pathways in B lymphocytes. Only recently have studies also investigated mechanisms involved in CD40 signaling in other cell types. Within monocytes, CD40 ligation results in the phosphorylation and activation of the MAPKs ERK-1/2. In fibroblasts, CD40 signaling mediated NF-κB mobilization [189, 190, 274]; within epithelial cells, CD40 ligation induced growth in a TRAF-3-dependent manner [272]. In smooth muscle cells, cross-linking of CD40 resulted in increased intracellular calcium concentrations, activation of protein tyrosine kinases, protein tyrosine phosphorylation, and activation of NF-κB [178].

Future studies will have to determine whether employment of TRAF family members reflects the (major) CD40 signaling pathway, whether these CD40-binding proteins interact with DNA directly or via other messengers/transcription factors, and whether differential equipment of certain cell types with TRAF family members, or differential use thereof, accounts for the diversity in responses to CD40 ligation.

7. Biological function of the CD40/CD154 dyad

Since numerous studies have addressed the role of CD40 signaling in humoral immunity and various excellent reviews have documented these findings, we will address this issue only briefly and refer to previous publications for further detail [28, 118, 119, 273–279].

7.1. T cell-dependent humoral immunity

The interaction between CD40 and CD154 is crucial for primary and secondary thymus-dependent humoral immune responses, and for the maturation towards memory B lymphocytes. Beside the mitogenic function, CD40/CD154 interactions further regulate the expression of costimulatory factors. Activation of naïve T lymphocytes requires both: the antigen-specific signaling via engagement of the TCR and the signaling via costimulatory molecules, such as the CD80/CD86 system, which interacts with CD28 on T lymphocytes. The first signaling pathway induces the expression of CD154 on the T lymphocyte, which via direct interactions can augment levels of costimulatory factors such as CD80/CD86 on B lymphocytes or other APCs, which in turn can amplify the activation of the T lymphocyte. Such activated T lymphocytes can initiate the secondary (humoral or cellular immune) response by regulating the activation and proliferation of naïve and mature B lymphocytes, switching of immunoglobulin classes, rescue from apoptosis, formation of germinal center cells, and the maturation toward memory cells.

7.1.1. Activation of B lymphocytes. Initial studies reported that ligation of CD40 via recombinant CD154 or anti-CD40 antibodies on human B lymphocytes elevated cell volume [100, 102], a process that correlated with the induction of intracellular, cell surface, and soluble markers, such as adhesion molecules, causing homotypic aggregation of freshly isolated human B cells via ICAM/LFA-1 [100, 230, 280], as well as VLA-4-dependent adhesion of B lymphocytes to endothelium [281]. CD40 ligation furthermore elevates the expression of other cell surface markers, including the low-affinity IgE receptor CD23 [57, 117], CD30 [282], CD80 (B7.1) and CD86 (B7.2) [63, 283–285], Fas [286, 287], and MHC class II [273]. In addition, CD40 ligation triggers the expression of the soluble cytokines IL-6, IL-10, TNF-α, TNF-β, and TGF-β [208, 288–290]. In contrast, CD40 ligation reduces the expression of CD8 [291]. Although the function of several of these mediators remains to be determined, most studies implicate CD40/CD154 interactions in modulation of B lymphocyte growth and differentiation.

The induction of B lymphocyte proliferation was the original function employed to isolate the first anti-CD40 antibodies. Resting as well as activated B lymphocyte subpopulations, including naïve, memory, germinal center CD5− and CD5+ B lymphocytes respond to CD40 ligation with enhanced proliferation rates [292, 293]. However, CD40 ligation supports only limited, short-term (< 10 days) proliferation. Long-term proliferation requires a costimulatory signal, e.g., via multivalent immunoglobulin cross-linking [294, 295] or cytokines, such as IL-4 and IL-10 [8, 11, 116, 292, 296–299]. Interestingly, IFN-α significantly inhibited CD40-mediated proliferation of normal tonsillar B lymphocytes [300].

In addition to NF-κB [301], control of B lymphocyte proliferation may involve the phosphoinositide 3-kinase subunit p85α and its splice variants p55α and p50α. Mice genetically deficient for these proteins show diminished numbers of peripheral mature B lymphocytes and proliferative response to CD40 ligation, a phenotype resembling observations in mice deficient in the tyrosine kinase Btk [302].

7.1.2. Switching of immunoglobulin classes. Probably the most intensely studied biological function of CD40 ligation on human B lymphocytes is the switch in recombination and synthesis of immunoglobulins, the prevalent mediators of this leukocyte subpopulation. CD40 signaling is essential for thymus-dependent induction of

immunoglobulin isotype synthesis itself as well as for the switching of the isotype of the heavy chain. Despite the impressive number of published studies, whether CD40 signaling (without further costimuli) is sufficient to mediate isotype switching remains controversial. Although some studies demonstrated that engagement of CD40 in the absence of other stimuli suffices to induce switching to IgG or IgA in human B cells [288, 303], several studies indicated that switching to at least certain immunoglobulin classes might require, or be potentiated by, the presence of certain comediators, e.g., T helper cell-derived cytokines, such as IL-4 or IL-10 [304–309]. Further studies also suggested that bidirectional modulation of immunoglobulin synthesis via cytokines: IL-2 and IL-10 specifically enhance IgM, IgG1, and IgA production, whereas IL-4, despite costimulating B lymphocyte proliferation, does not augment secretion of these isotypes, but rather provides an essential cosignal with CD154 for the production of IgG4 and IgE [310]. Cosignaling via cytokines has also been implicated in CD40-mediated IgD production; however, few data exist regarding synthesis of this immunoglobulin class, as reviewed elsewhere [118].

The dependence on CD40 signaling in combination with the requirement for comediators has been investigated in some detail for the synthesis of the primary immunoglobulin isotype generated during the T cell-dependent humoral response, IgM. Although probably predominantly mediated by CD40 (anti-CD40 treatment completely abolishes the primary IgM response in vivo [13]), IgM synthesis is potentiated in the presence of IL-2, IL-4, IL-5, and/or IL-10 [298, 310–312].

Induction of IgE expression seems to require both CD40- and IL-4-mediated signaling, which can be further enhanced by IL-5, IL-6, and/or IL-10, probably involving an autocrine feedback loop [298, 306, 310–316]. In addition, IL-13, which has high homology to IL-4, can support IgE synthesis, probably independently of IL-4 [317]. Regarding the immunoglobulin switch towards IgE, molecular mechanisms have been discovered that suggest that cytokines, such as IL-4, modulate isotype switching via the activation of certain DNA-binding proteins, e.g., an IL-4 nuclear factor interacting with the IL-4-responsive element in the ε switch region, thus inducing Cε germline transcript expression as well as class switching to IgE [315, 318]. This Cε germline transcription and switch recombination is opposed by IFN-γ and IFN-α, TGF-β, retinoic acid, and IL-6 [319–323].

Regarding the synergistic interaction of CD40 and IL-4 on the production of immunoglobulins, recent studies have proposed the formation of additional, STAT-6- and NF-κB/Rel protein-containing nuclear complexes. These complexes bind to the CD154/IL-4-responsive region of the respective promoter and thus enhance the activation via CD40 ligation, which mediates binding of NF-κB/Rel proteins to two tandem κB sites [324]. Similarly, studies have identified an evolutionary conserved sequence upstream of the human Ig heavy-chain Sγ3 region that acts as an inducible promoter, containing cis elements that critically mediate CD154- and IL-4-triggered transcriptional activation of the human Cγ3 gene [260]. This sequence provides a tandem NF-κB/Rel-binding motif, which is critical for the responsiveness to both CD154 and IL-4. However, activation via IL-4 requires an additional STAT-6-binding site. Further studies demonstrated that the transcription factor B cell-specific activator protein (BSAP) might be the merging point of the two signaling pathways, since it enhances both IL-4- and CD154-mediated activation of the human ε germline promoter [325]. Interestingly, CD40-mediated differentiation of non-antigen-selected human B cells is critically regulated by CD30, which inhibits the Ig switching, possibly through interference with the CD40-mediated, NF-κB-dependent, transcriptional activation of downstream C(H) genes [282].

7.1.3. Formation of germinal center and memory cells. The CD40 and CD154 receptor-ligand dyad affect the formation and survival of germinal center as well as memory B cells. One of the first functions implicating the CD40/CD154 dyad in the formation of germinal centers was the achievement of survival of freshly isolated centrocytes via CD40 ligation, as reviewed in detail elsewhere [326, 327]. CD40 signaling on germinal center cells furthermore increases the expression of surface immunoglobulin, and shifts their development towards memory cells. In accordance with this hypothesis are further studies indicating that CD40 ligation plays an indirect rather than a direct role in germinal center formation, since CD40 signaling bidirectionally activates T lymphocytes to induce secretion of cytokines required for germinal center formation and B lymphocytes to express the respective cytokine receptors [328]. Within advanced germinal centers, the bidirectional activation might also prime B lymphocytes for evolution toward memory cells [329]. Arpin et al. [293] demonstrated that prolonged stimulation of CD40 signaling on germinal center B lymphocytes in the presence of IL-2 and IL-10 mediates differentiation into memory cells, whereas lack of the ligand in this system results in differentiation toward plasma cells.

7.1.4. Activation of T lymphocytes via CD154. Although signaling following ligation of CD40 by CD154 was originally considered restricted to B lymphocytes, several studies demonstrated that cross-linking of CD154 on T lymphocytes provides costimulatory signals in the development of T helper responses. In vitro studies demonstrated that induction of IL-4 expression via CD3 and/or CD28 requires costimulation of T cells with CD154 [330]. In accordance with the role of IL-4 in the development of T helper cells, in vivo studies revealed that costimula-

Table 2. Biological functions of CD40 ligation.

	Function	Cell type	Mediator
Humoral immunity	activation	B lymphocytes	CD23, CD30, CD80, CD86, Fas, MHCII; cytokines: IL-6, IL-10, TNB-α, TGF-β
	Ig class switching	B lymphocytes	IgA, IgD (?), IgE, IgG, IgM
	Formation of germinal center and memory cells	B lymphocytes	cytokines: IL-2, IL-10; cytokine receptors
Cellular immunity	pro-inflammatory cytokines	B lymphocytes eosinophils monocytes dendritic cells epithelial cells fibroblasts keratinocytes endothelial cells smooth muscle cells	IL-1, IL-2, IL-4, IL-8, IL-10, IL-12, TNF-α, TGF-β
	chemokines	monocytes epithelial cells fibroblasts keratinocytes endothelial cells	IL-8, MIP-1α, MIP-1β, RANTES, MCP-1 ABCD-1: CCR7 (diminished CCR1/5)
	adhesion molecules	B lymphocytes endothelial cells fibroblasts	LFA-1, ICAM-1, VCAM-1, E-selectin, VLA-4
	matrix metalloproteinases	monocytes fibroblasts endothelial cells smooth muscle cells	interstitial collagenase 1 and 3 (MMP-1, MMP-13), gelatinase A and B (MMP-2,MMP-9), stromelysin 1 (MMP-3) and 3 (MMP-11)
	procoagulant activites	monocytes endothelial cells smooth muscle cells	tissue factor
	others	monocytes dendritic cells fibroblasts endothelial cells	Cox-2, nitric oxide

tion of T lymphocytes via CD154 is associated with the differentiation into T helper cells, modulating humoral immune responses of B lymphocytes [331].

7.2. Regulation of inflammatory mediators

Originally considered restricted to thymus-dependent humoral immunity, CD40/CD154 interactions might also participate in the development of cell-mediated immune responses. Substantial data now implicate CD40 signaling in the priming as well as effector functions of T lymphocytes. Ligation of CD40 activates proinflammatory processes in other leukocytic as well as non-leukocytic cells, including macrophages, NK cells, endothelial and smooth muscle cells, keratinocytes, and fibroblasts, as outlined in table 2 and discussed in detail below.

7.2.1 Cytokines. The cytokine network connects numerous immune and inflammatory processes involving leukocytic as well as non-leukocytic cell types. Ligation of CD40 on normal human blood B lymphocytes can stimulate the synthesis of IL-2, IL-6, IL-10, TNF-α, lymphotoxin α, and TGF-β [208, 288–290, 332–334]. Among the first indications of functional CD40 on cell types other than B lymphocytes was the report on the induction of GM-CSF expression [19], originally observed in thymic epithelial cells, and later also reported in follicular dendritic cells [335] and eosinophils [137]. Originally thought to require cytokines as costimulators [23], ligation of CD40 alone was eventually found to trigger expression of cytokines, such as TNF-α, IL-1, IL-6, or IL-8, in peripheral blood monocytes [144]. The CD40-mediated induction of IL-1β and TNF-α may follow activation of the MEK/ERK pathway, which is

antagonized by signals generated through the action of IL-4 and IL-10 [229]. Independent groups reported similar observations, with the exception of TNF-α, in human vascular endothelial cells [22]. CD40-mediated IL-6 production, mostly associated with enhanced proliferation of the respective cell type, has been described in multiple myeloma cells [336], in synovial membrane and dermal fibroblasts [104, 191], in keratinocytes [182], and in other non-hematopoetic cells [271]. CD40 ligation-induced IL-8 expression in fibroblasts [190], macrophages, or dendritic cells has been associated with the production of active IL-12 in these APCs [141, 337, 338], a process occurring during responses to T cell-dependent antigens. Interestingly, IL-12 can augment CD154 expression on T lymphocytes, indicating potential paracrine activation of the CD40/CD154 and/or IL-12 pathway [146]. The CD40-induced expression of IL-12 probably results from activation of NF-κB [339], and is inhibited in the presence of IL-10 and, less efficiently, also by IL-4, a finding associated with the processes resulting in priming of a Th1/Th2 response [340]. Furthermore, CD40-induced IL-12 may regulate IFN-γ production in peripheral blood monocytes [341]. However, whether CD40/CD154 interactions are essential for the induction of these Th1 immune response mediators remains to be determined, since the expression of both IL-12 and IFN-γ in CD154-deficient mice did not differ from that in wild-type mice [342].

7.2.2. Chemokines. Although the induction of IL-8 in mononuclear phagocytes was reported several years ago [23, 144], CD40-mediated induction of chemotactic mediators has only recently attracted interest. CD40 ligation induces expression of IL-8 in keratinocytes [183], fibroblasts [195], and epithelial cells [343]. Moreover, CD40 signaling also induces MCP-1, RANTES, MIP-1α and MIP-1β expression in proximal tubular epithelial cells [343], endothelial cells [92], and macrophages and macrophage-derived dendritic cells [344, 345]. Recently, ABCD-1 was identified as a CD40-inducible chemokine in B lymphocytes. This mediator is thought to play an important role in the collaboration of dendritic cells and B lymphocytes with T cells during immune responses [346]. Some groups have reported that the CD40-mediated expression of chemokines is enhanced by costimulation with cytokines such as IL-4, IL-13 [347], or IFN-γ [205]. Interestingly, ligation of CD40 does not necessarily result in the upregulation of chemokines: CD40 ligation, while stimulating the production of the other chemokines, caused a pronounced reduction of myeloid progenitor inhibitory factor 1 (MPIF-1) on human dendritic cells [348]. Moreover, recent reports demonstrated that chemokine receptors might be regulated differentially: maturation of dendritic cells by CD154 induces rapid downregulation of the CC chemokine receptors CDR-1 and CCR-5, but slow upregulation in the expression of CCR-7 [345, 349, 350].

7.2.3. Adhesion molecules. The induction of adhesion molecule expression was among the first biological consequences reported for CD40/CD154 interactions. Original reports, however, focused on its function in humoral rather than cellular immunity. Several studies demonstrated that CD40 signaling induces CD18/ICAM-1 (CD54)- and CD11a/CD18 (LFA-1)-mediated adhesion in B lymphocytes [230, 280], which implicates IgE synthesis by modulating Cε germline transcription [351]. Further studies revealed that CD40/CD154 interactions also mediate heterotopic adhesion. Treatment with an activating anti-CD40 antibody induced the heterotypic adhesion of normal B lymphocytes and B cells lines to both untreated and IL-1-stimulated endothelial cells via the interaction between the very late antigen 4 (VLA-4) and VCAM-1 [281]. In 1995, several groups transferred the idea of CD40-induced adhesion molecule expression into cellular immunity: a trimeric form of recombinant murine CD40 ligand induced the expression of leukocyte adhesion molecules, such as E-selectin, VCAM-1, and ICAM-1 on human vascular and umbilical vein endothelial cells [20, 22, 24], as well as on synovial membrane or dermal fibroblasts [104]. Furthermore, CD40 ligation on HIV-infected endothelial cells stimulated the preferential induction of VCAM-1, thus promoting B lymphoma cell growth through attachment, indicating a potential pathway through which viruses may induce malignancies [106].

These findings suggested the hypothesis that endothelial CD40 might serve as a crucial signaling receptor in the development of T lymphocyte-mediated (chronic) inflammatory reactions. Kinetic studies demonstrated that CD40/CD154-mediated activation of endothelial cells follows the time course of adhesion molecule induction observed with IL-1 or TNF-α, inducing peak levels of E-selectin after 4 h and of ICAM-1 after 24 h of stimulation [352]. CD40-mediated expression of adhesion molecules has further been described for CD54 on dendritic cells [338] and keratinocytes [183]. Later studies associated CD40-mediated expression of adhesion molecules with pathogenic processes underlying prevalent human diseases. Reed-Sternberg cells, regarded as the malignant components of Hodgkin's disease, as well as myeloma cell lines upregulate expression of adhesion molecules, such as CD54, LFA-1, or ICAM-2, upon CD40 ligation [353, 354]. Recent studies revealed that CD40 ligation induces the expression of the 86-kDa subunit of the Ku autoantigen, which functions as an adhesion molecule and mediates homotypic and heterotypic adhesion of multiple myeloma cells, probably providing autocrine and paracrine proliferation and promoting survival [355].

7.2.4. Extracellular matrix-degrading activities. The first evidence of CD40-medited expression of extracellular matrix-degrading activity referred to the enhanced expression of MMPs in mononuclear phagocytes. Stimulation with a CD154-positive T cells line or via recombinant soluble CD154 induced the expression of interstitial collagenase 1 (MMP-1), gelatinase A (MMP-2; 72-kDa gelatinase), gelatinase B (MMP-9; 92-kDa gelatinase), and stromelysin 1 (MMP-3) mRNA and protein in the human monocytic cell line THP-1 as well as peripheral blood monocytes and monocyte-derived macrophages [142, 143]. MMP gene transcription was induced within 6 h, followed by the respective immunoreactive protein detectable after 12–24 h stimulation. Ligation of CD40 induces the expression of the above-mentioned MMPs as well as interstitial collagenase 3 (MMP-13) and stromelysin-3 (MMP-11) also in human vascular endothelial [356] and smooth muscle cells [179, 180, 357]. These studies also demonstrated that CD40/CD154 interactions do not, or only weakly, affect the expression of endogenous tissue inhibitors of MMPs (TIMPs), suggesting that CD40 ligation shifts the balance toward enhanced enzymatic activity. However, counterregulatory mechanisms for the expression of MMP following CD40 ligation have been reported. In gingival fibroblasts, CD40 signaling resulted in the diminished expression of MMP-1 and MMP-3, while MMP-2 and TIMP-1 production were unaffected [194]. Recent reports showed that CD40 ligation enhanced transcription of the MMP-9 gene in osteosarcoma and Ewing's sarcoma cells [203], further supporting a role for CD40 as a functional receptor engaged in tumor cell survival and malignancy (as also reviewed below). In addition, CD40-mediated expression of matrix-degrading activities has been associated with other chronic inflammatory diseases, such as multiple sclerosis and atherosclerosis [358, 359; see also below].

7.2.5. Procoagulant activities. Studies performed in the early 1980s demonstrated that activated T lymphocytes can induce procoagulant activity on human vascular cells as well as peripheral blood mononuclear cells. Smariga and Maynard [360] demonstrated that platelets stimulate tissue factor expression, the initiator of the extrinsic coagulation pathway, in fibroblasts and smooth muscle cells in vitro. In addition, Gregory and Edgington [361] demonstrated that monocyte tissue factor expression is mediated by CD4+ T helper cells via an apparent contact-dependent mechanism. These findings were later attributed to CD40/CD154-mediated tissue factor expression [143, 362]. Interestingly, the CD40-mediated induction of tissue factor is not inhibitable by IL-10, the cytokine that counteracts various other functions with CD40 [362]. Moreover, the transiently induced tissue factor expression peaks after 6–12 h, differing from other CD154-indued mediators, e.g., cytokines or MMPs. Recently, the CD40-mediated induction of tissue factor on human vascular endothelial cells has drawn attention. Three groups [93, 363, 364], as well as our own [unpublished data], demonstrated that CD40 ligation directly regulates endothelial cell procoagulant activity during inflammatory responses by inducing tissue factor expression and diminishing thrombomodulin expression. CD40 signaling in these experiments was induced via soluble, as well as platelet or T lymphocyte-associated CD154. These findings imply that CD40/CD154 interactions directly modulate endothelial cell procoagulant activity during inflammatory responses, such as wound healing or atherosclerosis.

7.2.6. Other inflammatory mediators. CD40 engagement on human lung fibroblasts increases proinflammatory prostaglandin E_2 synthesis, a process mediated through the induction of cyclooxygenase-2 (Cox-2) [192]. This finding agrees with the report that treatment with anti-CD154 antibodies reduces the oxygen-induced induction of Cox-2 in a mouse model of hyperoxic lung injury [365]. Studies in our own laboratory further demonstrated that ligation of CD40 on atheroma-associated human vascular endothelial and smooth muscle cells also upregulates the expression of Cox-2 [366].

Furthermore, CD40 signaling in macrophages and dendritic cells has been associated with activation of nitric oxide synthase and thus the production of nitric oxide, a molecule that has recently obtained much attention in the context of chronic inflammatory diseases [367–369].

7.3. Apoptosis

Reviewing publications addressing the role of CD40/CD154 in apoptosis fully reveals the controversy of data published on these immune mediators. As discussed above, disparate findings might be explained by the use of (i) cell lines versus primary-culture cells, (ii) different cell types or cell lines, and (iii) similar cell types of different origins or activation status, as reviewed elsewhere [206]. The use of immortalized cell lines for studies of cell death seems questionable and the data obtained with such cell types should be viewed from this perspective. In addition, apoptosis, independent of its triggers, apparently reflects a complex biological process, involving a variety of known (and probably even more unknown) mediators, which act at different levels, and mediate opposing processes, e.g., prevention or induction of apoptosis. CD40-mediated processes in the context of apoptosis have been implicated in both humoral and cellular immunity.

The demonstration that activation through the antigen receptor in combination with a surface glycoprotein recognized by CD40 antibodies prevents centrocytes from undergoing apoptosis probably denotes one of the

first associations of the CD40/CD154 dyad with programmed cell death [370]. Later studies concluded that the protection against Fas-dependent apoptosis afforded by immunoglobulin-receptor engagement may constitute a fail-safe mechanism that eliminates bystander B lymphocytes activated by CD154-bearing T lymphocytes, and at the same time ensures survival of antigen-specific B cells [371]. The rescue of germinal center cells is furthermore thought crucial for the development of high-affinity antibody-producing memory cells. Several studies have demonstrated that ligation of CD40 prevents surface Ig-mediated apoptosis in B lymphocytes [372–375]. These processes correlate with elevated bcl-X, bcl-2 and decreased c-myc expression [376–381], although opposing findings have been reported [382–385]. The controversial findings observed in the regulation of bcl family members are probably explained by their differential regulation during CD40 activation in cells of different location and/or differentiation [386, 387]. Interestingly, bcl-X rather than bcl-2 has been associated with the rescue of centrocytes during germinal center selection [388], and CD40 ligation has been demonstrated to enhance the expression of mediators such as bcl-X_L in several B lymphocyte subpopulations and cell types [387–396].

Although these studies support anti-apoptotic functions of CD40/CD154 interactions, other studies revealed that CD40 ligation induces the expression and/or activation of caspase family members, such as CPP-32 [397, 398], implicating the receptor/ligand dyad in apoptosis. However, whether this is due to a direct mechanism, or whether CD40 ligation primes cells to become more sensitive for apoptosis induced by other pathways (e.g., via CD95) remains unclear. These processes might involve bcl family members and/or the upregulation of Fas [286, 287, 371, 399–402]. As nicely summarized by Kehry [206], directly induced apoptosis has been exclusively observed in cell lines rather than native cells, and thus might be interpreted with the appropriate caution. Accordingly, ligation of CD40 on normal B lymphocytes induces, on B lymphoma cells inhibits proliferation [403].

Furthermore, the nature of an initial activation signal might determine the fate of activated B lymphocytes after (re)engagement of the antigen receptor [404, 405]. Regarding the regulation of B lymphocyte survival, two pathways have been suggested: spontaneous apoptosis occurring in the absence of CD40 ligation during early phases or, following ligation of CD40, germinal B lymphocytes undergo apoptosis when encountering Fas, a process reversible by immunoglobulin receptor signaling. Interestingly, CD40 ligation also sensitizes mature germinal center B lymphocytes to immunoglobulin receptor-mediated cell death [406].

CD40 signaling has furthermore been associated with apoptosis in cells other than B lymphocytes: CD40 ligation assists in clonal expansion of CD4+ thymocytes (but not in activation-induced cell death) [171], rescues monocytes from apoptosis [407], and counteracts Fas-induced apoptosis of human dendritic cells [408], as well as TNF-induced apoptosis in a fibroblast cell line [409]. On the other hand, engagement of CD40 induces apoptosis in neuronal cells [410] and hepatocytes [85], further demonstrating the proapoptotic potential of CD40 signaling.

The finding that CD40 ligation induces death of transformed cells of non-lymphocytic origin, e.g., mesenchymal and epithelial tissue [411], initiated intense research on the importance of CD40/CD154 interactions in the treatment of cancer, e.g., by the induction of apoptosis in carcinoma/lymphoma cells [412]. The demonstration that CD40 ligation also inhibits apoptosis on blood dendritic cells [413] generated further interest in this mechanism for the prevention of drug-induced cell death [414, 415; see also next section]. Furthermore, sensitivity to Fas-induced apoptosis can be increased by CD40 ligation on neoplastic B lymphocytes, indicating an impediment to the development of Fas-based therapies [416]. Accordingly, leukemic B lymphocytes show defective CD40-mediated signal transduction and diminished CD95 receptor expression, which prevents the induction of apoptosis in these cells [417]. However, recent data demonstrating that CD40 ligation directly inhibits human breast carcinoma cells in vitro and in vivo seem to confirm the potential of CD154 for clinical applications [418, 419]. Further studies will have to evaluate whether these effects require interaction with IL-12, as suggested by Esche et al. [420], who demonstrated IL-12-dependent and -independent mechanisms of CD154-induced antitumor immunity [420].

As shown above for other functions, CD154 and cytokines, such as IL-4, IL-10, IL-13, or IFN-γ, also interact during apoptosis [375, 393, 421, 422], as demonstrated for the rescue of human B lymphocytes from cell death by coordinated signaling through CD40 and IL-4 [423].

8. CD40/CD154 in human diseases

In the previous sections, we reviewed the molecular and biochemical characteristics as well as the potential biological functions of the CD40/CD154 dyad. We will now focus on the association of CD40 signaling with human diseases. The majority of studies correlate elevated CD40/CD154 expression with pathological processes, thus suggesting interruption of CD40 signaling as a potential pharmaceutic target. The first association of CD40 with a human disease was related to the discovery of this molecule on human urinary bladder carcinoma and malignant B lymphocytes, e.g., Burkitt

lymphoma cells and Epstein-Barr virus-transformed lymphoblastoid cell lines [2, 3, 99, 120]. These studies, however, lacked evidence of causal association.

8.1. Hyper-IgM syndrome

The first detailed information regarding the importance of CD40 signaling in disease pathogenesis in vivo was provided by the discovery that mutations in the CD154 gene cause an X-linked immunodeficiency, termed the X-linked hyper-IgM syndrome (HIGM) [10, 424, 425]. This primary immunodeficiency disorder is characterized by low levels of IgG, IgA, elevated or normal levels of IgM, and a lack of germinal center formation, thus preventing isotype switching and somatic mutations [16, 156, 424–429]. The decreased levels of the transcript or synthesis of non-functional CD154 result from missense, nonsense, splice site, and/or deletion/insertion mutations [430–433]. A database of CD154 gene mutations causing X-linked HIGM is available [430]. Interestingly, CD4 + T cell lines established from HIGM patients with leaky splice site mutations show an association of full-length and truncated mutants with wild-type CD154. The clinical phenotype of these patients, characterized by a severe impairment of T cell-dependent humoral immune responses, and lack of circulating IgG, IgA, and IgE, as well as memory cells, suggests that this association results in less efficient cross-linking of CD40 [434]. Besides failed expression of CD154 by T lymphocytes, defects in CD40-mediated signal transduction in B lymphocytes cause HIGM [435]. In accordance with these findings, induced genetic deficiency in CD40 and/or CD154 induced similar symptoms in mice [436–438].

8.2. Infectious disease

8.2.1. Viral pathogens. The association between viral infections and the CD40/CD154 receptor/ligand dyad has been studied in detail for the human and simian immunodeficiency virus, demonstrating as early as 1991 that infection of CD4 + T lymphocytes correlates with the expression of CD40 on their cell surface [439]. Although HIV-infected T lymphocytes do not express CD154 [440], and thus cannot account for the hypergammaglobulinemia observed in patients, later studies demonstrated that CD40 signaling might be more than just a bystander in this process, since (i) the interaction of CD4 with gp120 blocks the expression of CD154 on T lymphocytes following anti-CD3-mediated activation (thus probably contributing to the hyporesponsiveness of these cells during HIV infection) [441]; (ii) CD40 signaling affects virus replication, although it is controversial whether it enhances [442–444] or reduces the replication rate [345]; (iii) CD40 ligation induces expression of the chemokines MIP-1α, MIP-1β, RANTES, and MCP-1 [344] and, finally, (iv) the infection of microvascular endothelial cells induced surface expression of CD40 [106]. The latter finding is of particular interest with respect to the observation that HIV infections are associated with the development of aggressive extranodal B cell non-Hodgkin's lymphomas that express CD154 and that interruption of CD40/CD154 interactions inhibits the attachment of those B lymphocytes, potentially reducing HIV-promoted B lymphoma cell growth, which is facilitated by the attachment of lymphoma cells to HIV-infected endothelial cells, probably resulting in malignancies.

Apart from HIV, viral infections in general have been associated with CD40 signaling. Original studies showed a direct anti-viral activity of CD154, which was proposed as a potent effector mechanism of T lymphocytes activated during a virus infection [445]. Infections of CD154-deficient mice with several viruses, including lymphocytic choriomeningitis virus, Pichinde virus, or vesicular stomatitis virus, revealed severely compromised humoral immune responses, suggesting that IgG1 responses are totally dependent on functional CD154, whereas moderate titers of anti-viral IgM and some IgG2a, IgG2b, and IgG3 were produced [446]. Whether effective primary cytotoxic lymphocyte (CTL) responses depend on CD154 is controversial, since opposing findings on the impairment in CTL function and lack of generation of CTL memory cells, germinal centers, and B memory lymphocytes in CD154-deficient mice have been reported [447].

8.2.2. Intra/extracellular microorganisms. Beyond infections with viral pathogens, CD40/CD154 interactions may participate in the immune response initiated by infections via intracellular as well as extracellular microogranisms. Probably due to the X-chromosomal location of the CD154 gene, men rather than women diagnosed for HIGM have an enhanced susceptibility to opportunistic infections, such as *Pneumocystis carinii* pneumonia and *Cryptosporidium* intestinal infections, as discussed in detail elsewhere [28, 448]. Recent studies implicated CD40-mediated IL-12/IFN-γ immune responses as essential to control infections by these intracellular organisms, providing a potential mechanism underlying the susceptibility of patients with HIGM syndrome to infections by opportunistic pathogens [449]. Analysis of the immune response of CD154-deficient mice following infection with the intracellular pathogen *Listeria monocytogenes* and various strains of *Leishmania* [450–453], as well as the extracellular pathogens *Borrelia burgdorferi* [454], *Heligmosomoides polygyrus* [455], and *P. carinii* [456], associated CD40 signaling with disease progression, e.g., via induction of nitric oxide [451] or IL-12 [452, 457, 458]. These findings are in accordance with the report that ligation of CD40 of

peritoneal macrophages prevents infection by *Trypanosoma cruzi* in mice, an effect that requires de novo synthesis of nitric oxide and IL-12 [459]. However, these data probably require further clarification since other studies demonstrated that at least for some intracellular pathogens, e.g., *Mycobacterium* or *Histoplasma capsulatium*, a proper immune response can be achieved independently of CD154 [342, 460].

8.3. Transplantation

Studies in CD40-deficient mice demonstrated that interruption of CD40 signaling reduces the grade of rejection, as originally shown for pancreatic islet allografts [461] and later also for skin and cardiac rejection [462–464], as well as splenocyte [463] or bone marrow [465, 466] transplantation. Interestingly, most previous studies demonstrated only incomplete inhibition of chronic rejection by interruption of CD40 signaling and implicated the requirement for sensitization with further alloantigens, such as CD28 [462, 467] or CTLA-4 [468–471], to achieve long-term survival of the grafts. However, a recent study demonstrated that treatment with anti-CD154 antibodies, without inhibition of further mediators, completely prevented rejection in primates [472]. Thus, a potentially bifunctional role of CD40 signaling might be postulated, mediating processes independent or dependent on other costimulatory pathways, such as the CD28/B7 system, as reviewed elsewhere [473]. Several studies have provided evidence that a reduction in proinflammatory mediators, such as nitric oxide synthase in macrophages and antibody synthesis in B lymphocytes is associated with the benefits observed following interruption of CD40 signaling.
Furthermore, blockade of CD40/CD154 interactions in combination with the inhibition of the CD28/B7 signaling pathways [447] reduced rejection by affecting cytokine production and proliferation of T lymphocytes [462, 463, 466]. With respect to the role of cytokines, the modulation of IFN-γ might be of particular interest, since this cytokine surprisingly facilitates rather than hinders induction of long-term allograft survival, which is considered to be due to limited expansion of activated T lymphocytes [474]. Indeed, IFN-γ-deficient mice demonstrated that CD40 ligation prevents neonatal allotolerance through an IFN-γ- (and IL-12)-dependent pathway [471, 475]. Anti-CD154 antibody-mediated lack of chronic rejection has also been correlated with vascular expression of the 'protective' genes heme oxygenase-1, bcl-x_L, and A20 [476]. Accordingly, expression of CD40 and CD154 is elevated in vivo on infiltrating leukocytes during cardiac and liver allograft rejection, probably interacting with microvascular endothelium [17, 96] and Kupffer cells [477].

8.4. Autoimmune disease

A potential role of CD40/CD154 interactions has been established for several autoimmune disease, including lupus nephritis [478], lupus erythematosus [89, 479], collagen-induced arthritis [480], experimental allergic encephalomyelitis [481–483], and multiple sclerosis [483, 484], as reviewed in detail elsewhere [485]. CD40 signaling has furthermore been associated with early events in the development of spontaneous autoimmune diabetes [486]. Application of anti-CD154 antibodies blocked the development of most of these diseases in the respective animal model [487], probably via modulation of T and/or B lymphocyte responses [488], or Fas-mediated apoptotic processes [489, 490]. Studies in CD154-deficient mice implicated in particular the costimulatory activity of CD154, e.g, via induction of IFN-γ expression in APCs for processes evoking autoimmunity [481, 482]. Among further CD40 signaling-dependent mediators implicated in the progression of autoimmune disease are IL-12 [491, 492], TNF-α [493], and CD80 [463]. Interestingly, T and B lymphocytes of lupus patients [89, 494] express high concentrations of CD154, further supporting the hypothesis of inappropriate CD40 signaling as a crucial participant in the pathogenesis of autoimmune disease, probably by mediating the production of potentially harmful autoantibodies.
In this regard, early studies had revealed that the cell surface of peripheral blood T lymphocytes in rheumatoid arthritis patients differs not only in MHC class II expression, but also in other activation markers, including CD40, from those of healthy persons [129]. Later studies demonstrated elevated expression of both CD40 [104, 495] and CD154 [496, 497] on CD4+/CD8+ T lymphocytes/macrophages of the synovial fluid of rheumatoid patients, where they might modulate development of synovium hyperplasia [188]. Further evidence for the association of CD40/CD154 dysfunction with rheumatoid arthritis has been provided by studies linking the HIGM syndrome with increased incidences of this autoimmune disease [498, 499]. However, the molecular pathways of CD40/CD154 interaction with autoimmune diseases, such as rheumatoid arthritis, remain to be determined.

8.5. Cardiovascular disease

Both immune mediators, CD40 and CD154, are overexpressed in human and experimental atherosclerotic lesions. Functional receptor and ligand are expressed on atheroma-associated endothelial cells, smooth muscle cells, and macrophages in situ and in vitro [18]. Thus, the role of the dyad within atherogenesis has gathered increasing attention during recent years. Among atheroma-associated processes induced via CD40 liga-

tion are the expression of matrix-degrading enzymes, such as MMP-1 (interstitial collagenase type I), MMP-2 (gelatinase A, 72-kDa gelatinase), MMP-3 (stromelysin-1), MMP-9 (gelatinase B, 92-kDa gelatinase), MMP-11 (stromelysin-3), and MMP-13 (interstitial collagenase type III) [142, 143, 179, 180, 356, 357], molecules considered crucial in the processes of plaque progression and finally plaque rupture. The acute thrombotic complications following plaque rupture are mediated through the procoagulant activities of the lipid core, such as tissue factor. Interestingly, CD40 ligation induces tissue factor expression in all three atheroma-associated cell types: endothelial cells, smooth muscle cells, and macrophages [93, 143, 362–364, 500]. Further atheroma-associated processes mediated by CD40 signaling include the induction of proinflammatory cytokines, such as IL-1, IL-6, or IL-8, as well as adhesion molecules, such as ICAM-1, E-selection, or VCAM [20, 22, 24]. Enhanced expression of such molecules, in combination with [probably CD40-mediated; 356] neovessel formation might contribute to the increased extravasation of inflammatory cells and to their accumulation at sites of atherogenesis [501]. This hypothesis is further supported by the finding that CD40 ligation induces the expression of chemokines, a potential pathway by which immune-competent cells might be attracted into deeper layers of the (inflamed) tissue [502]. Another CD40-regulated mediator probably involved in the processes of atherogenesis includes cycloocygenase (Cox)-2 [365]. We recently demonstrated that human atherosclerotic lesions indeed express increased levels of this so-called ‘inflammatory’ isoform [366], a finding with implications for neoangiogenesis as well [503].

The in vivo relevance of CD40/CD154 signaling in atherogenesis has been demonstrated in animal models. Treatment of hyperlipidemic low density lipoprotein receptor-deficient mice (Ldlr $-/-$) with an anti-murine CD154 antibody significantly reduced the formation of atherosclerotic lesions [175]. The validity of this observation was later confirmed in a study employing CD40L/apoE-deficient mice [504]. Moreover, Aukrust et al. [505] demonstrated enhanced levels of soluble and membrane-bound CD154 in patients with unstable angina. However, whether elevated serum levels of CD154 reflect a causal relationship of this immune mediator with the pathogenic processes of atherogenesis or whether this inflammatory marker is just a bystander remains to be determined.

Although the mechanisms of CD40 and CD154 expression within the atherosclerotic lesion are only poorly understood, one can reasonably postulate involvement of ‘classical’ activators such as IL-1, TNF-α, and in particular IFN-γ, which enhance both CD40 and CD154 expression in vitro and which are expressed within the lesion [506]. In addition, a recent report demonstrates that lysophosphatidylcholine, which accumulates within atherosclerotic plaques, also enhances CD154 expression at least in CD4+ T lymphocytes [507].

8.6. Cancer

Cancer was probably the first human disease associated with the CD40/CD154 signaling pathway, as CD40 was first described on the surface of neoplastic B lymphocytes and malignant cell types of non-hematopoietic origin [2, 3, 349, 99, 120]. Later studies extended these findings, associating CD40/CD154 with epithelial neoplasia [42, 99] as well as chronic lymphocytic, acute lymphoblastic, and hairy cell leukemia, non-Hodgkin’s lymphomas, nasopharyngeal carcinoma, osteosarcoma and Ewing’s sarcoma, myeloma, Hodgkin’s disease, melanoma, and bladder transitional-cell carcinomas [115, 123, 166, 169, 197, 198, 203, 508–511]. In accordance with the neoplastic nature of these CD40 sources are studies demonstrating that ligation of CD40 suppresses apoptosis in various cell types [384, 512]. As outlined above, CD40 ligation induces anti-apoptotic processes and stimulates DNA synthesis, triggering activated B lymphocytes to enter S phase, and eventually induces proliferation in those cells [120, 299, 513, 514]. Moreover, CD40 ligation rescues malignant and normal B lymphocytes from induced growth arrest [515]. The finding that ligation of CD40 enhances DNA synthesis and prevents apoptosis suggests a potential role for the CD40/CD154 signaling dyad in the initiation and/or evolution of cancer cells. Knowledge regarding the molecular mechanisms underlying these pro- and anti-apoptotic functions, however, remains sparse. In particular, the interaction of the CD40/CD154 dyad with the Fas signaling pathway has been implicated in malignancy. Cell type as well as timely sequence of interactions between the two mediators probably play a crucial role in the fate of carcinoma cells. Ligation of CD40 before that of CD95 renders Hodgkin’s disease cell lines refractory to Fas-induced apoptosis [516]. This hypothesis is supported by recent studies revealing that expression of CD40 by B lymphocytes from chronic lymphocytic leukemia patients is similar to that of normal patients’, whereas CD40 signaling is defective. This correlates with diminished CD95 expression and lack of induction of apoptosis following ligation of CD95 in these cells, demonstrating a potential pathway of long-term survival in leukemic cells [417].

In addition to B lymphocytes, CD40 signaling on other cell types, such as endothelial cells in Karposi’s sarcoma [174], benign juvenile and lobular capillary hemangiomas [172], epidermal tumors [185], and renal cell carcinoma [173] is also considered relevant for the progression of the respective disease. Moreover, T lymphocytes have been implicated in the finding that leukemia cell-mediated downmodulation of CD154 on activated T lymphocytes accounts for some of the acquired immune defects of patients with chronic lymphocytic leukemia [517].

In accordance with the elevated expression and potential functions of CD40 in cancer, the immune mediator may provide a marker for tumor cells [198] as well as a potential target for therapeutic intervention in the treatment of B cell lymphomas and other forms of cancer [202]. Original studies revealed that treatment with anti-CD40 antibodies inhibits the proliferation of murine B lymphoma cells [403, 518] and human breast carcinoma cells in vitro and in vivo [204]. Treatment with anti-CD40 antibodies also diminishes the development of Epstein-Barr virus-mediated human B cell lymphoma [519]. The potential role of CD40/CD154 interaction in cellular tumor immunity in vivo has been further established in CD154-deficient mice, which lack the protective immunity against syngeneic tumors generated in wild-type mice by the administration of tumor vaccines [520, 521]. Moreover, ligation of CD40 eradicates syngeneic lymphoma in mice and provides protection against repeated tumor challenge, which French et al. [522] interpret as a potential immunization against syngeneic tumors.

Similar studies have revealed that transducing tumor cells with CD154 can mediate rejection and/or create a long-lasting systemic immune response capable of impeding growth of unmodified neuroblastoma cells [523, 524], and that CD154 can enhance the immune response against leukemia [525] and squamous cell carcinoma [526]. Thus, patients with chronic lymphocytic leukemia, who demonstrate lack of CD154 on peripheral blood T lymphocytes, acquire an immunodeficiency with characteristics similar to those of patients with inherited defects in the gene encoding CD154 [517]. Other studies, however, demonstrated that serum of patients with chronic lymphocytic leukemia contained elevated levels of biologically active soluble CD154, and that the ligand prolongs survival of leukemia cells and mediates their resistance to apoptosis, at least in vitro [88, 383]. These findings imply that both interruption or enhancement of CD40/CD154 interactions might benefit patients, depending on the particular nature of the cancer treated. In accordance with this hypothesis, experiments employing BALB/c mice demonstrated that challenge with a lethal dose of tumor can be overcome by vaccination with plasmids encoding CD154, preventing development of metastatic tumors, and implicating CD154 cDNA treatment as a potential vaccine adjuvant [458]. Results of another study support the concept that transduction of tumor cells with recombinant CD154 adenovirus vector might provide a treatment for cancer immunotherapy, since treatment of established subcutaneous tumors resulted in sustained tumor regression and tumor-free status in $>60\%$ of the mice [527]. Furthermore, recent studies suggest that CD154 gene transfer into tumor cells may induce tumoricidal activity of host alveolar macrophages, thus further supporting the potential for this strategy of cancer gene therapy [528]. However, there are potential limitations to this therapeutic approach. Injection of a retroviral vector containing the cDNA for murine CD154 in CD154-deficient mice effectively stimulates humoral and cellular immune functions short term, but causes T cell lymphoproliferative disorders long term [529]. Furthermore, activation of CD40/CD154 signaling might prove counterproductive in some circumstances, since ligation of CD40 inhibits the cytotoxic effect of the anti-cancer drug doxorubicin in non-Hodgkin's lymphoma cell lines, probably by abrogating caspase-3 activation, thus mediating resistance to chemotherapy in lymphoma cells [415]. An alternative strategy focuses on the use of immunotoxins. The demonstration that immunotoxins targeted against CD40, either in chemical conjugate form [115] or as single-chain immunotoxins [530, 531], mediate anti-tumor activity in vitro and in vivo suggested the potential for therapeutic use, which will require further confirmation.

8.7. Other human diseases

CD40/CD154 interactions have recently been implicated in lung disorders, although expression of the molecules on basophils [134] within lung tissue was described nearly a decade ago. Later studies localized CD40 also on fibroblasts [186], macrophages [532], and endothelial cells [24] of lung tissue, as well as bronchial epithelial cells [98]. CD40 was initially associated with lung disorders by the finding that ligation of CD40 induces expression of IgE as well as inflammatory mediators, such as cytokines or Cox-2 [192, 365, 533] in human lung mast cells, blood basophils, and eosinophils implicating a role for the CD40/CD154 dyad during allergy [79]. Accordingly, treatment of wild-type mice with CD154 protein induced pulmonary inflammatory reactions, which were not observed in identically treated CD40 gene-deficient mice [534]. Furthermore, artificially induced airway inflammation was not attenuated in CD40-deficient mice compared to wild-type mice [533, 535]. Recent studies provide evidence that bone marrow-derived CD40+ cells are required for the induction of pulmonary inflammation and that alveolar macrophages, B and T lymphocytes rather than fibroblasts, epithelial cells, or endothelial cells can establish pulmonary inflammation [536]. Interruption of CD40/CD154 interactions has recently been suggested as a potential pharmaceutical target for intervention for oxygen-induced acute respiratory distress syndrome [365], and radiation-induced pulmonary toxicity [537].

In summary, elevated expression and interaction of the CD40/CD154 receptor/ligand dyad is associated with the progression of many prevalent human diseases. Accordingly, animal models have revealed evidence for the

therapeutic potential of anti-CD40L antibody treatment However, whether these techniques can be applied to humans remains to be determined, since treatment with ('humanized') antibodies has obvious limitations. Unfortunately, no effective synthetic small molecule inhibitors of CD40/CD154 interactions have been reported, leaving humanized antibodies as the most propagated choice for therapeutic intervention.

Acknowledgments. This work was performed during the tenure of the Paul Dudley White fellowship of the American Heart Association by Dr. Uwe Schönbeck, and further supported by grants from the National Heart, Lung, and Blood Institute to Peter Libby (HL-34636, HL-56985).

1 Paulie S., Koho H., Ben-Aissa H., Hansson Y., Lundblad M. L. and Perlmann P. (1984) Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. II. Identification of the cellular target structures by immunoprecipitation and SDS-PAGE analysis. Cancer Immunol. Immunother. **17:** 173–179

2 Koho H., Paulie S., Ben-Aissa H., Jonsdottir I., Hansson Y., Lundblad M. L. et al. (1984) Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence. Cancer Immunol. Immunother. **17:** 165–172

3 Paulie S., Ehlin-Heriksson B., Mellstedt H., Koho H., Ben-Aissa H. and Perlmann P. (1985) A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother. **20:** 23–28

4 Clark E. A. and Ledbetter J. A. (1986) Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA **83:** 4494–4498

5 Hirohata S., Jelinek D. F. and Lipsky P. E. (1988) T cell-dependent activation of B cell proliferation and differentiation by immobilized monoclonal antibodies to CD3. J. Immunol. **140:** 3736–3744

6 Bartlett W. C., Michael A., McCann J., Yuan D., Claassen E. and Noelle R. J. (1989) Cognate interactions between helper T cells and B cells. II. Dissection of cognate help by using a class II-restricted, antigen-specific, IL-2-dependent helper T cell clone. J. Immunol. **143:** 1745–1754

7 Bartlett W. C., McCann J., Shepherd D. M., Roy M. and Noelle R. J. (1990) Cognate interactions between helper T cells and B cells. IV. Requirements for the expression of effector phase activity by helper T cells. J. Immunol. **145:** 3956–3962

8 Armitage R. J., Fanslow W. C., Strockbine L., Sato T. A., Clifford K. N., Macduff B. M. et al. (1992) Molecular and biological characterization of a murine ligand for CD40. Nature **357:** 80–82

9 Lederman S., Yellin M. J., Krichevsky A., Belko J., Lee J. J. and Chess L. (1992) Identification of a novel surface protein on activated Cd4 + T cells that induces contact-dependent B cells differentiation (help). J. Exp. Med. **175:** 1091–1101

10 Graf D., Korthauer U., Mages H. W., Senger G. and Kroczek R. A. (1992) Cloning of TRAP, a ligand for CD40 on human T cells. Eur. J. Immunol. **22:** 3191–3194

11 Hollenbaugh D., Grosmaire L. S., Kullas C. D., Chalupny N. J., Braesch-Andersen S., Noelle R. J. et al. (1992) The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. **11:** 4313–4321

12 Noelle R. J., Foy T. M., Shepherd D. M., Stamenkovic I., Ledbetter J. A. and Aruffo A. (1992) A 39-kD protein on activated helper T cells binds, CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA **98:** 6550–6554

13 Foy T. M., Shepherd D. M., Durie F. H., Aruffo A., Ledbetter J. A. and Noelle R. J. (1993) In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med. **178:** 1567–1575

14 Van den Eertwegh A. J., Noelle R. J., Roy M., Shepherd D. M., Aruffo A., Ledbetter J. A. et al. (1993) In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. **18:** 1555–1565

15 Foy T. M., Laman J. D., Ledbetter J. A., Aruffo A., Claassen E. and Noelle R. J. (1994) gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. **180:** 157–163

16 Callard R. E., Armitage R. J., Fanslow W. C. and Spriggs M. K. (1993) CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today **14:** 559–564

17 Briscoe D. M., Alexander S. I. and Lichtman A. H. (1998) Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr. Opin. Immunol. **10:** 525–531

18 Mach F., Schönbeck U., Sukhova G. K., Bourcier T., Bonnefoy J. Y., Pober J. S. et al. (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA **94:** 1931–1936

19 Galy A. H. and Spits H. (1992) CD40 is functionally expressed on human thymic epithelial cells. J. Immunol. **149:** 775–782

20 Hollenbaugh D., Mischel-Petty N., Edwards C. P., Simon J. C., Denfeld R. W., Kiener P. A. et al. (1995) Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. **182:** 33–40

21 Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I. et al. (1994) Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. **180:** 1263–1272

22 Karmann K., Hughes C. C., Schechner J., Fanslow W. C. and Pober J. S. (1995) CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA **92:** 4342–4346

23 Alderson M. R., Armitage R. J., Tough T. W., Strockbine L., Fanslow W. C. and Spriggs M. K. (1993) CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. **178:** 669–674

24 Yellin M. J., Brett J., Baum D., Matsushima A., Szabolcs M., Stern D. et al. (1995) Functional interactions of T cells with endothelial cells: the role of CD40-CD40-mediated signals. J. Exp. Med. **182:** 1857–1864

25 Smith C. A., Farrah T. and Goodwin R. G. (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell **76:** 959–962

26 Tsitsikov E. N., Ramesh N. and Geha R. S. (1994) Structure of the murine CD40 ligand gene. Mol. Immunol. **31:** 895–900

27 Villa A., Notarangelo L. D., Di Santo J. P., Macchi P. P., Strina D., Frattini A. et al. (1994) Organization of the human CD40L gene: implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. Proc. Natl. Acad. Sci. USA **91:** 2110–2114

28 Kotten C. van and Banchereau J. (1996) CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv. Immunol. **61:** 1–77

29 Bajorath J., Chalupny N. J., Marken J. S., Siadak A. W., Skonier J., Gordon M. et al. (1995) Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry **34:** 1833–1844
30 Bajorath J., Marken J. S., Chalupny N. J., Spoon T. L., Siadak A. W., Gordon M. et al. (1995) Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry **34:** 9884–9892
31 Graf D., Muller S., Korthauer U., Kooten C. van, Weise C. and Kroczek R. A. (1995) A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. **25:** 1749–1754
32 Ludewig B., Henn V., Schroder J. M., Graf D. and Kroczek R. A. (1996) Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur. J. Immunol. **26:** 3137–3143
33 Wykes M., Poudrier J., Lindstedt R. and Gray D. (1998) Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur. J. Immunol. **28:** 548–559
34 Hsu Y. M., Lucci J., Su L., Ehrenfels B., Garber E. and Thomas D. (1997) Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J. Biol. Chem. **272:** 911–915
35 Gearing A. J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H. et al. (1994) Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature **370:** 555–557
36 McGeehan G. M., Becherer J. D., Bast R. C. Jr, Boyer C. M., Champion B., Connolly K. M. et al. (1994) Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature **370:** 558–561
37 Peitsch M. C. and Jongeneel C. V. (1993) A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int. Immunol. **5:** 233–238
38 Karpusas M., Hsu Y. M., Wang J. H., Thompson J., Lederman S., Chess L. et al. (1995) 2 Å crystal structure of an extracellular fragment of human CD40 ligand. Structure **3:** 1031–1039
39 Singh J., Garber E., Van Vlijmen H., Karpusas M., Hsu Y. M., Zheng Z. et al. (1998) The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci. **7:** 1124–1135
40 Bajorath J. (1998) Detailed comparison of two molecular models of the human CD40 ligand with an X-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J. Biol. Chem. **273:** 24603–24609
41 Bajorath J. and Aruffo A. (1997) Construction and analysis of a detailed three-dimensional model of the ligand binding domain of the human B cell receptor CD40. Proteins **27:** 59–70
42 Stamenkovic I., Clark E. A. and Seed B. (1989) A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. **8:** 1403–1410
43 Ramesh N., Ramesh V., Gusella J. F. and Geha R. (1993) Chromosomal localization of the gene for human B-cell antigen CD40. Somat. Cell Mol. Genet. **19:** 295–298
44 Lafage-Pochitaloff M., Herman P., Birg F., Galizzi J. P., Simonetti J., Mannoni P. et al. (1994) Localization of the human CD40 gene to chromosome 20, bands q12–q13.2. Leukemia **8:** 1172–1175
45 Grimaldi J. C., Torres R., Kozak C. A., Chang R., Clark E. A., Howard M. et al. (1992) Genomic structure and chromosomal mapping of the murine CD40 gene. J. Immunol. **149:** 3921–3926
46 Hostager B. S., Hsing Y., Harms D. E. and Bishop G. A. (1996) Different CD40-mediated signaling events require distinct CD40 structural features. J. Immunol. **157:** 1047–1053
47 Goldstein M. D. and Watts T. H. (1996) Identification of distinct domains in CD40 involved in B7-1 induction or growth inhibition. J. Immunol. **157:** 2837–2843
48 Torres R. M. and Clark E. A. (1992) Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation. J. Immunol. **148:** 620–626
49 Braesch-Andersen S., Paulie S., Koho H., Nika H., Aspenstrom P. and Perlmann P. (1989) Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40. J. Immunol. **142:** 562–567
50 Van Den Berg T. K., Hasbold J., Renardel De Lavalette C., Dopp E. A., Dijkstra C. D. and Klaus G. G. (1996) Properties of mouse CD40: differential expression of CD40 epitopes on dendritic cells and epithelial cells. Immunology **88:** 294–300
51 Banner D. W., D'Arcy A., Janes W., Gentz R., Schoenfeld H. J., Broger C. et al. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell **73:** 431–445
52 Naismith J. H., Devine T. Q., Brandhuber B. J. and Sprang S. R. (1995) Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J. Biol. Chem. **270:** 13303–13307
53 Gauchat J. F., Aubry J. P., Mazzei G., Life P., Jomotte T., Elson G. et al. (1993) Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett. **315:** 259–266
54 Roy M., Waldschmidt T., Aruffo A., Ledbetter J. A. and Noelle R. J. (1993) The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J. Immunol. **151:** 2497–2510
55 Hermann P., Kooten van C., Gaillard C., Banchereau J. and Blanchard D. (1995) CD40 ligand-positive CD8+ T cell clones allow B cell growth and differentiation. Eur. J. Immunol. **25:** 2972–2977
56 Horner A. A., Jabara H., Ramesh N. and Geha R. S. (1995) Gamma/delta T lymphocytes express CD40 ligand and induce isotype switching in B lymphocytes. J. Exp. Med. **181:** 1239–1244
57 Lederman S., Yellin M. J., Inghirami G., Lee J. J., Knowles D. M. and Chess L. (1992) Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles: roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J. Immunol. **149:** 3817–3826
58 Casamayor-Palleja M., Khan M. and MacLennan I. C. (1995) A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J. Exp. Med. **181:** 1293–1301
59 Castle B. E., Kishimoto K., Streans C., Brown M. L. and Kehry M. R. (1993) Regulation of expression of the ligand for CD40 on T helper lymphocytes. J. Immunol. **151:** 1777–1788
60 Pinchuk L. M., Klaus S. J., Magaletti D. M., Pinchuk G. V., Norsen J. P. and Clark E. A. (1996) Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J. Immunol. **157:** 4363–4370
61 Jaiswal A. I., Dubey C., Swain S. L. and Croft M. (1996) Regulation of CD40 ligand expression on naïve CD4 T cells: a role for TCR but not co-stimulatory signals. Int. Immunol. **8:** 275–285
62 Nusslein H. G., Frosch K. H., Woith W., Lane P., Kalden J. R. and Manger B. (1996) Increase of intracellular calcium is the essential signal for the expression of CD40 ligand. Eur. J. Immunol. **26:** 846–850
63 Roy M., Aruffo A., Ledbetter J., Linsley P., Kehry M. and Noelle R. (1995) Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. **25:** 596–603
64 Johnson-Leger C., Christensen J. and Klaus G. G. (1998) CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells. Int. Immunol. **10:** 1083–1091

65 Ding L., Green J. M., Thompson C. B. and Shevach E. M. (1995) B7/CD28-dependent and -independent induction of CD40 ligand expression. J. Immunol. **155:** 5124–5132
66 Lane P., Traunecker A., Hubele S., Inui S., Lanzavecchia A. and Gray D. (1992) Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participants in T cell-dependent activation of B lymphocytes. Eur. J. Immunol. **22:** 2573–2578
67 Hermann P., Blanchard D., de Saint-Vis B., Fossiez F., Gaillard C., Vanbervliet B. et al. (1993) Expression of a 32-kDa ligand for the CD40 antigen on activated human T lymphocytes. Eur. J. Immunol. **23:** 961–964
68 Fuleihan R., Ramesh N., Horner A., Ahern D., Belshaw P. J., Albert D. G. et al. (1994) Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J. Clin. Invest. **93:** 1315–1320
69 Lobo F. M., Zanjani R., Ho N., Chatila T. A. and Fuleihan R. L. (1999) Calcium-dependent activation of TNF family gene expression by Ca^{2+}/calmodulin kinase type IV/Gr and calcineurin. J. Immunol. **162:** 2057–2063
70 Tsytsykova A. V., Tsitsikov E. N. and Geha R. S. (1996) The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J. Biol. Chem. **271:** 3763–3770
71 Schubert L. A., King G., Cron R. Q., Lewis D. B., Aruffo A. and Hollenbaugh D. (1995) The human gp39 promoter: two distinct nuclear factors of activated T cell protein-binding elements contribute independently to transcriptional activation. J. Biol. Chem. **270:** 29624–29627
72 Black R. A. and White J. M. (1998) ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. **10:** 654–659
73 Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F. et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature **385:** 729–733
74 Moss M. L., Jin S. L., Milla M. E., Bickett D. M., Burkhart W., Carter H. L. et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature **385:** 733–736
75 Paganelli R., Scala E., Ansotegui I. J., Ausiello C. M., Halapi E., Fanales-Belasio E. et al. (1995) CD8+ T lymphocytes provide helper activity for IgE synthesis in human immunodeficiency virus-infected patients with hyper-IgE. J. Exp. Med. **181:** 423–428
76 Sad S., Krishnan L., Bleackley R. C., Kagi D., Hengartner H. and Mosmann T. R. (1997) Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity. Eur. J. Immunol. **27:** 914–922
77 Fuleihan R., Ahern D. and Geha R. S. (1995) CD40 ligand expression is developmentally regulated in human thymocytes. Clin. Immunol. Immunopathol. **76:** 52–58
78 Brugnoni D., Airo P., Graf D., Marconi M., Lebowitz M., Plebani A. et al. (1994) Ineffective expression of CD40 ligand on cord blood T cells may contribute to poor immunoglobulin production in the newborn. Eur. J. Immunol. **24:** 1919–1924
79 Gauchat J. F., Henchoz S., Mazzei G., Aubry J. P., Brunner T., Blasey H. et al. (1993) Induction of human IgE synthesis in B cells by mast cells and basophils. Nature **365:** 340–343
80 Yanagihara Y., Kajiwara K., Basaki Y., Ikizawa K., Akiyama K. and Saito H. (1997) Induction of human IgE synthesis in B cells by a basophilic cell line, KU812. Clin. Exp. Immunol. **108:** 295–301
81 Yanagihara Y., Kajiwara K., Basaki Y., Ikizawa K., Ebisawa M., Ra C. et al. (1998) Cultured basophils but not cultured mast cells induce human IgE synthesis in B cells after immunologic stimulation. Clin. Exp. Immunol. **111:** 136–143
82 Gauchat J. F., Henchoz S., Fattah D., Mazzei G., Aubry J. P., Jomotte T. et al. (1995) CD40 ligand is functionally expressed on human eosinophils. Eur. J. Immunol. **25:** 863–865
83 Cocks B. G., Waal Malefyt R. de, Galizzi J. P., Vries J. E. de and Aversa G. (1993) IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int. Immunol. **5:** 657–663
84 Gaweco A. S., Wiesner R. H., Yong S., Krom R., Porayko M., Chejfec G. et al. (1999) CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection. Liver Transplant. Surg. **5:** 1–7
85 Afford S. C., Randhawa S., Eliopoulos A. G., Hubscher S. G., Young L. S. and Adams D. H. (1999) CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J. Exp. Med. **189:** 441–446
86 Carbone E., Ruggiero G., Terrazzano G., Palomba C., Manzo C., Fontana S. et al. (1997) A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J. Exp. Med. **185:** 2053–2060
87 Grammer A. C., Bergman M. C., Miura Y., Fujita K., Davis L. S. and Lipsky P. E. (1995) The CD40 ligand expressed by human B cells costimulates B cells responses. J. Immunol. **154:** 4996–5010
88 Clodi K., Asgary Z., Zhao S., Kliche K. O., Cabanillas F., Andreeff M. et al. (1998) Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br. J. Haematol. **103:** 270–275
89 Devi B. S., Van Noordin S., Krausz T. and Davies K. A. (1998) Peripheral blood lymphocytes in SLE-hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J. Autoimmunity **11:** 471–475
90 Desai-Mehta A., Lu L., Ramsey-Goldman R. and Datta S. K. (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. **97:** 2063–2073
91 Blossom S., Chu E. B., Weigle W. O. and Gilbert K. M. (1997) CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J. Immunol. **159:** 4580–4586
92 Henn V., Slupsky J. R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G. et al. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature **391:** 591–594
93 Slupsky J. R., Kalbas M., Willuweit A., Henn V., Kroczek R. A. and Muller-Berghaus G. (1998) Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb. Haemost. **80:** 1008–1014
94 Pawankar R., Okuda M., Yssel H., Okumura K. and Ra C. (1997) Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J. Clin. Invest. **99:** 1492–1499
95 Masten B. J., Yates J. L., Pollard Koga A. M. and Lipscomb M. F. (1997) Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L. Am. J. Respir. Cell Mol. Biol. **16:** 335–342
96 Reul R. M., Fang J. C., Denton M. D., Geehan C., Long C., Mitchell R. N. et al. (1997) CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation **64:** 1765–1774
97 Gaweco A. S., Mitchell B. L., Lucas B. A., McClatchey K. D. and Van Thiel D. H. (1999) CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection. Kidney Int. **55:** 1543–1552
98 Gormand F., Briere F., Peyrol S., Raccurt M., Durand I., Ait-Yahia S. et al. (1999) CD40 expression by human bronchial epithelial cells. Scand. J. Immunol. **49:** 355–361
99 Ledbetter J. A., Shu G., Gallagher M. and Clark E. A. (1987) Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). J. Immunol. **138:** 788–794

100 Gordon J., Millsum M. J., Guy G. R. and Ledbetter J. A. (1988) Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen: a comparison with IL-4-mediated signaling. J. Immunol. **140:** 1425–1430
101 Paulie S., Rosen A., Ehlin-Henriksson B., Braesch-Andersen S., Jakobson E., Koho H. et al. (1989) The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction. J. Immunol. **142:** 590–595
102 Valle A., Zuber C. E., Defrance T., Djossou O., De Rie M. and Banchereau J. (1989) Activation of human B lymphocytes through CD40 and interleukin 4. Eur. J. Immunol. **19:** 1463–1467
103 Clark E. A., Shu G. L., Luscher B., Draves K. E., Banchereau J., Ledbetter J. A. et al. (1989) Activation of human B cells: comparison of the signal transduced by IL-4 to four different competence signals. J. Immunol. **143:** 3873–3880
104 Yellin M. J., Winikoff S., Fortune S. M., Baum D., Crow M. K., Lederman S. et al. (1995) Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J. Leukoc. Biol. **58:** 209–216
105 McLellan A. D., Sorg R. V., Williams L. A. and Hart D. N. (1996) Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur. J. Immunol. **26:** 1204–1210
106 Moses A. V., Williams S. E., Strussenberg J. G., Heneveld M. L., Ruhl R. A., Bakke A. C. et al. (1997) HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas. Nat. Med. **3:** 1242–1249
107 Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R. et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. **64:** 2309–2318
108 Law C. L., Wormann B. and LeBien T. W. (1990) Analysis of expression and function of CD40 on normal and leukemic human B cell precursors. Leukemia **4:** 732–738
109 Henderson R. A., Watkins S. C. and Flynn J. L. (1997) Activation of human dendritic cells following infection with *Mycobacteital tuberculosis*. J. Immunol. **159:** 635–643
110 Gilliam A. C., Kremer I. B., Yoshida Y., Stevens S. R., Tootell E., Teunissen M. B. et al. (1998) The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J. Invest. Dermatol. **110:** 422–427
111 Krzesz R., Wagner A. H., Cattaruzza M. and Hecker M. (1999) Cytokine-inducible CD40 gene expression in vascular smooth muscle cells is mediated by nuclear factor kappaB and signal transducer and activation of transcription-1. FEBS Lett. **453:** 191–196
112 Craxton A., Shu G., Graves J. D., Saklatvala J., Krebs E. G. and Clark E. A. (1998) p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J. Immunol. **161:** 3225–3236
113 Nguyen V. T., Walker W. S. and Benveniste E. N. (1998) Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-beta. Eur. J. Immunol. **28:** 2537–2548
114 Saeland S., Duvert V., Caux C., Pandrau D., Farve C., Valle A. et al. (1992) Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells. Exp. Hematol. **20:** 24–33
115 Uckun F. M., Gajl-Peczalska K., Myers D. E., Jaszcz W., Haissig S. and Ledbetter J. A. (1990) Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood **76:** 2449–2459
116 Banchereau J., Paoli P. de, Valle A., Garcia E. and Rousset F. (1991) Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science **251:** 70–72
117 Saeland S., Duvert V., Moreau I. and Banchereau J. (1993) Human B cell precursors proliferate and express CD23 after CD40 ligation. J. Exp. Med. **178:** 113–120
118 Clark L. B., Foy T. M. and Noelle R. J. (1996) CD40 and its ligand. Adv. Immunol. **63:** 43–78
119 Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J. P., Kooten C. van et al. (1994) The CD40 antigen and its ligand. Annu. Rev. Immunol. **12:** 881–922
120 Beiske K., Clark E. A., Holte H., Ledbetter J. A., Smeland E. B. and Godal T. (1988) Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40: responses differ from normal blood B cells and are restricted to certain morphologic subsets. Int. J. Cancer. **42:** 521–528
121 Pellat-Deceunynck C., Bataille R., Robillard N., Harousseau J. L., Rapp M. J., Juge-Morineau N. et al. (1994) Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood **84:** 2597–2603
122 Westendorf J. J., Ahmann G. J., Lust J. A., Tschumper R. C., Griepp P. R., Katzmann J. A. et al. (1995) Molecular and biological role of CD40 in multiple myeloma. Curr. Top. Microbiol. Immunol. **194:** 63–72
123 Westendorf J. J., Ahmann G. J., Armitage R. J., Spriggs M. K., Lust J. A., Greipp P. R. et al. (1994) CD40 expression in malignant plasma cells: role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J. Immunol. **152:** 117–128
124 Kooten C. van, Gaillard C., Galizzi J. P., Hermann P., Fossiez F., Banchereau J. et al. (1994) B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur. J. Immunol. **24:** 787–792
125 Bjorck P., Braesch-Andersen S. and Paulie S. (1994) Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40. Immunology **83:** 430–437
126 Fluckiger A. C., Sanz E., Garcia-Lloret M., Su T., Hao Q. L., Kato R. et al. (1998) In vitro reconstitution of human B-cell ontogeny: from CD34(+) multipotent progenitors to Ig-secreting cells. Blood **92:** 4509–4520
127 Herbst B., Kohler G., Mackensen A., Veelken H., Kulmburg P., Rosenthal F. M. et al. (1996) In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type. Blood **88:** 2541–2548
128 Flores-Romo L., Bjorck P., Duvert V., Kooten C. van, Saeland S. and Banchereau J. (1997) CD40 ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J. Exp. Med. **185:** 341–349
129 Potocnik A. J., Kinne R., Menninger H., Zacher J., Emmrich F. and Kroczek R. A. (1990) Expression of activation antigens on T cells in rheumatoid arthritis patients. Scand. J. Immunol. **31:** 213–224
130 Were C. F., Crowe P. D., Vanarsdale T. L., Andrews J. L., Grayson M. H., Jerzy R. et al. (1991) Tumor necrosis factor (TNF) receptor expression in T lymphocytes: differential regulation of the type I TNF receptor during activation of resting and effector T cells. J. Immunol. **147:** 4229–4238
131 Indzhiia L. V., Yakovleva L. A., Overbaugh J., Licciardi K. A., Chikobava M. G., Klotz I. N. et al. (1992) Baboon T cell lymphomas expressing the B cell-associated surface proteins CD40 and Bgp95. J. Clin. Immunol. **12:** 225–236
132 Armitage R. J., Tough T. W., Macduff B. M., Fanslow W. C., Spriggs M. K., Ramsdell F. et al. (1993) CD40 ligand is a T cell growth factor. Eur. J. Immunol. **23:** 2326–2331
133 Fanslow W. C., Clifford K. N., Seaman M., Alderson M. R., Spriggs M. K., Armitage R. J. et al. (1994) Recombinant CD40 ligand exerts potent biologic effects on T cells. J. Immunol. **152:** 4262–4269

134 Valent P., Majdic O., Maurer D., Bodger M., Muhm M. and Bettelheim P. (1990) Further characterization of surface membrane structures expressed on human basophils and mast cells. Int. Arch. Allergy Appl. Immunol. **91:** 198–203
135 Blom T., Nilsson G., Sundstrom C., Nilsson K. and Hellman L. (1996) Characterization of a human basophil-like cell line (LAMA-84). Scand. J. Immunol. **44:** 54–61
136 Valent P., Besemer J., Kishi K., Kaltenbrunner R., Kuhn B., Maurer D. et al. (1990) IL-3 promotes basophilic differentiation of KU812 cells through high affinity binding sites. J. Immunol. **145:** 1885–1889
137 Ohkawara Y., Lim K. G., Xing Z., Glibetic M., Nakano K., Dolovich J. et al. (1996) CD40 expression by human peripheral blood eosinophils. J. Clin. Invest. **97:** 1761–1766
138 Reischl I. G., Pollabauer E. M., Peiritsch S., Schlager S., Gladstone P., Vooijs W. C. et al. (1996) The 'monocytic' cell line 1937 displays typical B cell characteristics. Immunol. Lett. **49:** 127–131
139 Wanger D. H. Jr, Stout R. D. and Suttles J. (1994) Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur. J. Immunol. **24:** 3148–3154
140 Kennedy M. K., Picha K. S., Fanslow W. C., Grabstein K. H., Alderson M. R., Clifford K. N. et al. (1996) CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. **26:** 370–378
141 Kato T., Hakamada R., Yamane H. and Nariuchi H. (1996) Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J. Immunol. **156:** 3932–3938
142 Malik N., Greenfield B. W., Wahl A. F. and Kiener P. A. (1996) Activation of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol. **156:** 3952–3960
143 Mach F., Schönbeck U., Bonnefoy J. Y., Pober J. S. and Libby P. (1997) Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation **96:** 396–399
144 Kiener P. A., Moran-Davis P., Rankin B. M., Wahl A. F., Aruffo A. and Hollenbaugh D. (1995) Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J. Immunol. **155:** 4917–4925
145 DeKruyff R. H., Gieni R. S. and Umetsu D. T. (1997) Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J. Immunol. **158:** 359–366
146 Peng X., Remacle J. E., Kasran A., Huylebroeck D. and Ceuppens J. L. (1998) IL-12 up-regulates CD40 ligand (CD154) expression on human T cells. J. Immunol. **160:** 1166–1172
147 Kremer I. B., Cooper K. D., Teunissen M. B. and Stevens S. R. (1998) Low expression of CD40 and B7 on macrophages infiltrating UV-exposed human skin: role in IL-2Ralpha-T cell activation. Eur. J. Immunol. **28:** 2936–2946
148 Zanussi S., D'Andrea M., Simonelli C., Trabattoni D., Bortolin M. T., Caggiari L. et al. (1999) The effects of CD40 ligation on peripheral blood mononuclear cell interleukin-12 and interleukin-15 production and on monocyte CD14 surface antigen expression in human immunodeficiency virus-positive patients. Scand. J. Immunol. **49:** 286–292
149 Freudenthal P. S. and Steinman R. M. (1990) The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl. Acad. Sci. USA **87:** 7698–7702
150 Clark E. A., Grabstein K. H. and Shu G. L. (1992) Cultured human follicular dendritic cells: growth characteristics and interactions with B lymphocytes. J. Immunol. **148:** 3327–3335
151 Lenz A., Heine M., Schuler G. and Romani N. (1993) Human and murine dermis contain dendritic cells: isolation by means of a novel method and phenotypical and functional characterization. J. Clin. Invest. **92:** 2587–2596
152 Peguet-Navarro J., Dalbiez-Gautheir C., Rattis F. M., Kooten C. van, Banchereau J. and Schmitt D. (1995) Functional expression of CD40 antigen on human epidermal Langerhans cells. J. Immunol. **155:** 4241–4247
153 Canque B., Camus S., Yagello M. and Gluckman J. C. (1998) IL-4 and CD40 ligation affect differently the differentiation, maturation, and function of human CD34+ cell-derived CD1a+CD14− and CD1a−CD14+ dendritic cell precursors in vitro. J. Leukoc. Biol. **64:** 235–244
154 Strobl H., Scheinecker C., Riedl E., Csmarits B., Bello-Fernandez C., Pickl W. F. et al. (1998) Identification of CD68+lin− peripheral blood cells with dendritic precursor characteristics. J. Immunol. **161:** 740–748
155 Brossart P., Grunebach F., Stuhler G., Reichardt V. L., Mohle R., Kanz L. et al. (1998) Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood **92:** 4238–4247
156 Facchetti F., Appiani C., Salvi L., Levy J. and Notarangelo L. D. (1995) Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immundeficiency with hyper-IgM: abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J. Immunol. **154:** 6624–6633
157 Ludewig B., Graf D., Gelderblom H. R., Becker Y., Kroczek R. A. and Pauli G. (1995) Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur. J. Immunol. **25:** 1943–1950
158 Kim H. S., Zhang X., Klyushnenkova E. and Choi Y. S. (1995) Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK. J. Immunol. **155:** 1101–1109
159 Foy T. M., Page D. M., Waldschmidt T. J., Schoneveld A., Laman J. D., Masters S. R. et al. (1995) An essential role for gp39, the ligand for CD40, in thymic selection. J. Exp. Med. **182:** 1377–1388
160 Mackey M. F., Barth R. J. Jr and Noelle R. J. (1998) The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukoc. Biol. **63:** 418–428
161 Kooten C. van and Banchereau J. (1997) Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. **9:** 330–337
162 Ni K. and O'Neill H. C. (1997) The role of dendritic cells in T cell activation. Immunol. Cell Biol. **75:** 223–230
163 Ria F., Penna G. and Adorini L. (1998) Th1 cell induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. Eur. J. Immunol. **28:** 2003–2016
164 Snijders A., Kalinski P., Hilkens C. M. and Kapsenberg M. L. (1998) High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. **10:** 1593–1598
165 Petrasch S., Brittinger G., Wacker H. H., Schmitz J. and Kosco-Vilbois M. (1994) Follicular dendritic cells in non-Hodgkin's lymphomas. Leukoc. Lymphoma **15:** 33–43
166 Vyth-Dreese F. A., Boot H., Dellemijn T. A., Majoor D. M., Oomen L. C., Laman J. D. et al. (1998) Localizatin in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology **94:** 580–586
167 Thomas R., Davis L. S. and Lipsky P. E. (1994) Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J. Immunol. **152:** 2613–2623
168 Young L. S., Dawson C. W., Brown K. W. and Rickinson A. B. (1989) Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int. J. Cancer **43:** 786–794
169 Zong Y. S., Lin H., Choy D. T., Sham J. S., Wei W., Chan K. H. et al. (1991) Nasopharyngeal carcinoma and lymphinfiltration. Oncology **48:** 290–296
170 Patel D. D., Whichard L. P., Radcliff G., Denning S. M. and Haynes B. F. (1995) Characterization of human thymic epithelial cell surface antigens: phenotypic similarity of

thymic epithelial cells to epidermal keratinocytes. J. Clin. Immunol. **15:** 80–92
171 Ruggiero G., Caceres E. M., Voordouw A., Noteboom E., Graf D., Kroczek R. A. et al. (1996) CD40 expressed on thymic epithelial cells provides costimulatin for proliferation but not for apoptosis of human thymocytes. J. Immunol. **156:** 3737–3746
172 Pammer J., Weninger W., Mazal P. R., Horvat R. and Tschachler E. (1996) Expression of the CD40 antigen on normal endothelial cells and in benign and malignant tumours of vascular origin. Histopathology **29:** 517–524
173 Kluth B., Hess S., Engelmann H., Schafnitzel S., Riethmuller G. and Feucht H. E. (1997) Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. **57:** 891–899
174 Pammer J., Plettenberg A., Weninger W., Diller B., Mildner M., Uthman A. et al. (1996) CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. Am. J. Pathol. **148:** 1387–1396
175 Mach F., Schönbeck U., Sukhova G. K., Atkinson E. and Libby P. (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature **394:** 200–203
176 Yellin M. J., D'Agati V., Parkinson G., Han A. S., Szema A., Baum D. et al. (1997) Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum. **40:** 124–134
177 Suo Z., Tan J., Placzek A., Crawford F., Fang C. and Mullan M. (1998) Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res. **807:** 110–117
178 Lazaar A. L., Amrani Y., Hsu J., Panettieri R. A. Jr, Fanslow W. C., Albelda S. M. et al. (1998) CD40-mediated signal transduction in human airway smooth muscle. J. Immunol. **161:** 3120–3127
179 Schönbeck U., Mach F., Sukhova G. K., Murphy C., Bonnefoy J. Y., Fabunmi R. P. et al. (1997) Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. **81:** 448–454
180 Schönbeck U., Mach F., Sukhova G. K., Atkinson E., Levesque E., Herman M. et al. (1999) Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med. **189:** 843–853
181 Wrone-Smith T., Johnson T., Nelson B., Boise L. H., Thompson C. B., Nunez G. et al. (1995) Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am. J. Pathol. **146:** 1079–1088
182 Gaspari A. A., Sempowski G. D., Chess P., Grish J. and Phipps R. P. (1996) Human epidermal keratinocytes are induced to secrete interleukin-6 and co-stimulate T lymphocyte proliferation by a CD40-dependent mechanism. Eur. J. Immunol. **26:** 1371–1377
183 Denfeld R. W., Hollenbaugh D., Fehrenbach A., Weiss J. M., Leoprechting A. von, Mai B. et al. (1996) CD40 is functionally expressed on human keratinocytes. Eur. J. Immunol. **26:** 2329–2334
184 Peguet-Navarro J., Dalbiez-Gauthier C., Moulon C., Berthier O., Reano A., Gauchaerand M. et al. (1997) CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. J. Immunol. **158:** 144–152
185 Viac J., Schmitt D. and Claudy A. (1997) CD40 expression in epidermal tumors. Anticancer Res. **17:** 569–572
186 Fries K. M., Sempowski G. D., Gaspari A. A., Blieden T., Looney R. J. and Phipps R. P. (1995) CD40 expression by human fibroblasts. Clin. Immunol. Immunopathol. **77:** 42–51
187 Banchereau J., Dubois B., Fayette J., Burdin N., Briere F., Miossec P. et al. (1995) Functional CD40 antigen on B cells, dendritic cells and fibroblasts. Adv. Exp. Med. Biol. **378:** 79–83
188 Rissoan M. C., Kooten C. van, Chomarat P., Galibert L., Durand I., Thivolet-Bejui F. et al. (1996) The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium. Clin. Exp. Immunol. **106:** 481–490
189 Smith T. J., Sempowski G. D., Bernson C. S., Cao H. J., Wang H. S. and Phipps R. P. (1997) Human thyroid fibroblasts exhibit a distinctive phenotype in culture: characteristic ganglioside profile and functional CD40 expression. Endocrinology **138:** 5576–5588
190 Sempowski G. D., Rozenblit J., Smith T. J. and Phipps R. P. (1998) Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am. J. Physiol. **274:** C707–714
191 Sempowski G. D., Chess P. R., Moretti A. J., Padilla J., Phipps R. P. and Blieden T. M. (1997) CD40 mediated activation of gingival and periodontal ligament fibroblasts. J. Periodontol. **68:** 284–292
192 Zhang Y., Cao H. J., Graf B., Meekins H., Smith T. J. and Phipps R. P. (1998) CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J. Immunol. **160:** 1053–1057
193 Cao H. J., Wang H. S., Zhang Y., Lin H. Y., Phipps R. P. and Smith T. J. (1998) Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J. Biol. Chem. **273:** 29615–29625
194 Wassenaar A., Verschoor T., Kievits F., Den Hartog M. T., Kapsenberg M. L., Everts V. et al. (1999) CD40 engagement modulates the production of matrix metalloproteinases by gingival fibroblasts. Clin. Exp. Immunol. **115:** 161–167
195 Sempowski G. D., Chess P. R. and Phipps R. P. (1997) CD40 is functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts. J. Immunol. **158:** 4670–4677
196 Kennedy I. C., Hart D. N., Colls B. M., Nimmo J. C., Willis D. A. and Angus H. B. (1989) Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's disease are probable dendritic cell malignancies. Clin. Exp. Immunol. **76:** 324–331
197 O'Grady J. T., Stewart S., Lowrey J., Howie S. E. and Krajewski A. S. (1994) CD40 expression in Hodgkin's disease. Am. J. Pathol. **144:** 21–26
198 Carbone A., Gloghini A., Gattei V., Aldinucci D., Degan M., De Paoli P. et al. (1995) Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood **85:** 780–789
199 Gruss H. J., Hirschstein D., Wright B., Ulrich D., Caligiuri M. A., Barcos M. et al. (1994) Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood **84:** 2305–2314
200 Gruss H. J., Ulrich D., Braddy S., Armitage R. J. and Dower S. K. (1995) Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur. J. Immunol. **25:** 2083–2089
201 Agathanggelou A., Niedobitek G., Chen R., Nicholls J., Yin W. and Young L. S. (1995) Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma: evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am. J. Pathol. **147:** 1152–1160
202 Oord J. J. van den, Maes A., Stas M., Nuyts J., Battocchio S., Kasran A. et al. (1996) CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol. **149:** 1953–1961
203 Lollini P. L., Landuzzi L., Frabetti F., Rossi I., Nicoletti G., Scotlandi K. et al. (1998) Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells. Clin. Cancer Res. **4:** 1843–1849
204 Wingett D. G., Vestal R. E., Forcier K., Hadjokas N. and Nielson C. P. (1998) CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res. Treat. **50:** 27–36

205 Altenburg A., Baldus S. E., Smola H., Pfister H. and Hess S. (1999) CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J. Immunol. **162:** 4140–4147
206 Kehry M. R. (1996) CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J. Immunol. **156:** 2345–2348
207 Fanslow W. C., Srinivasan S., Paxton R., Gibson M. G., Spriggs M. K. and Armitage R. J. (1994) Structural characteristic of CD40 ligand that determine biological function. Semin. Immunol. **6:** 267–278
208 Clark E. A. and Shu G. (1990) Association between IL-6 and CD40 signaling IL-6 induces phosphorylation of CD40 receptors. J. Immunol. **145:** 1400–1406
209 Inui S., Kaisho T., Kikutani H., Stamenkovic I., Seed B., Clark E. A. et al. (1990) Identification of the intractoplasmic region essential for signal transduction through a B cell activation molecule, CD40. Eur. J. Immunol. **20:** 1747–1753
210 Hu H. M., O'Rourke K., Boguski M. S. and Dixit V. M. (1994) A novel RING finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem. **269:** 30069–30072
211 Uckun F. M., Schieven G. L., Dibirdik I., Chandan-Langlie M., Tuel-Ahlgren L. and Ledbetter J. A. (1991) Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. **266:** 17478–17485
212 Ren C. L., Morio T., Fu S. M. and Geha R. S. (1994) Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J. Exp. Med. **179:** 673–680
213 Aagaard-Tillery K. M. and Jelinek D. F. (1996) Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J. Immunol. **156:** 4543–4554
214 Gulbins E., Brenner B., Schlottmann K., Koppenhoefer U., Linderkamp O., Coggeshall K. M. et al. (1996) Activation of the Ras signaling pathway by the CD40 receptor. J. Immunol. **157:** 2844–2850
215 Purkerson J. M. and Parker D. C. (1998) Differential coupling of membrane Ig and CD40 to the extracellularly regulated kinase signaling pathway. J. Immunol. **160:** 2121–2129
216 Goldstein M. D., Cochrane A. and Watts T. H. (1997) Cyclic-AMP modulates downstream events in CD40-mediated signal transduction, but inhibition of protein kinase A has no direct effect on CD40 signaling. J. Immunol. **159:** 5871–5880
217 Kato T., Kokuho T., Tamura T. and Nariuchi H. (1994) Mechanisms of T cell contact-dependent B cell activation. J. Immunol. **152:** 2130–2138
218 Francis D. A., Karras J. G., Ke X. Y., Sen R. and rothstein T. L. (1995) Induction of the transcription factors NF-kappa B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int. Immunol. **7:** 151–161
219 Yanagihara Y., Basaki Y., Ikizawa K. and Kajiwara K. (1997) Possible role of nuclear factor-kappa B activity in germline C epsilon transcription in a human Burkitt lymphoma B cell line. Cell Immunol. **176:** 66–74
220 Ren C. L., Fu S. M. and Geha R. S. (1994) Protein tyrosine kinase activation and protein kinase C translocation are functional components of CD40 signal transduction in resting human B cells. Immunol. Invest. **23:** 437–448
221 Huo L. and Rothstein T. L. (1996) Isolation and characterization of murine fra-1: induction mediated by CD40 and surface Ig is protein kinase C dependent. J. Immunol. **157:** 3812–3818
222 Kawakami K. and Parker D. C. (1993) Antigen and helper T lymphocytes activate B lymphocytes by distinct signaling pathways. Eur. J. Immunol. **23:** 77–84
223 Marshall L. S., Shepherd D. M., Ledbetter J. A., Aruffo A. and Noelle R. J. (1994) Signaling events during helper T cell-dependent B cell activation. I. Analysis of the signal transduction pathways triggered by activated helper T cell in resting B cells. J. Immunol. **152:** 4816–4825
224 Berberich I., Shu G., Siebelt F., Woodgett J. R., Kyriakis J. M. and Clark E. A. (1996) Cross-linking CD40 on B cells preferentially induces stress-activaed protein kinases rather than mitogen-activated protein kinases. EMBO J. **15:** 92–101
225 Sutherland C. L., Heath A. W., Pelech S. L., Young P. R. and Gold M. R. (1996) Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. **157:** 3381–3390
226 Kashiwada M., Kaneko Y., Yagita H., Okumura K. and Takemori T. (1996) Activation of mitogen-activated protein kinases via CD40 is distinct from that stimulated by surface IgM on B cells. Eur. J. Immunol. **26:** 1451–1458
227 Kashiwada M., Shirakata Y., Inoue J. I., Nakano H., Okazaki K., Okumura K. et al. (1998) Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway. J. Exp. Med. **187:** 237–244
228 Li Y. Y., Baccam M., Waters S. B., Pessin J. E., Bishop G. A. and Koretzky G. A. (1996) CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. J. Immunol. **157:** 1440–1447
229 Suttles J., Milhorn D. M., Miller R. W., Poe J. C., Wahl L. M. and Stout R. D. (1999) CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway: a target of interleukin IL-4 and IL-10 anti-inflammatory action. J. Biol. Chem. **274:** 5835–5842
230 Kansas G. S. and Tedder T. F. (1991) Transmembrane signals generated through MHC class II, CD19, CD20, CD40 antigens induce LFA-1 dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. **147:** 4094–4102
231 Knox K. A. and Gordon J. (1993) Protein tyrosine phosphorylation is mandatory for CD40-mediated rescue of germinal center B cells from apoptosis. Eur. J. Immunol. **23:** 2578–2584
232 Faris M., Gaskin F., Parsons J. T. and Fu S. M. (1994) CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein. J. Exp. Med. **179:** 1923–1931
233 Cheng G., Cleary A. M., Ye Z. S., Hong D. I., Lederman S. and Baltimore D. (1995) Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science **267:** 1494–1498
234 Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C. and Kieff E. (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell **80:** 389–399
235 Sato T., Irie S. and Reed J. C. (1995) A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett. **358:** 113–118
236 Franken M., Devergne O., Rosenzweig M., Annis B., Kieff E. and Wang F. (1996) Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J. Virol. **70:** 7819–7826
237 Eyndhoven W. G. van, Frank D., Kalachikov S., Cleary A. M., Hong D. I., Cho E. et al. (1998) A single gene for human TRAF-3 at chromosome 14q32.3 encodes a variety of mRNA species by alternative polyadenylation, mRNA splicing and transcription initiation. Mol. Immunol. **35:** 1189–1206
238 Rothe M., Sarma V., Dixit V. M. and Goeddel D. V. (1995) TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science **269:** 1424–1427

239 Chaudhuri A., Orme S., Vo T., Wang W. and Cherayil B. J. (1999) Phosphorylation of TRAF2 inhibits binding to the CD40 cytoplasmic domain. Biochem. Biophys. Res. Commun. **256:** 620–625
240 Chaudhuri A., Orme S., Eilam S. and Cherayil B. J. (1997) CD40-mediated signals inhibit the binding of TNF receptor-associated factor 2 to the CD40 cytoplasmic domain. J. Immunol. **159:** 4244–4251
241 Rothe M., Xiog J., Shu H. B., Williamson K., Goddard A. and Goeddel D. V. (1996) I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc. Natl. Acad. Sci. USA **93:** 8241–8246
242 Ishida T. K., Tojo T., Aoki T., Kobayashi N., Ohishi T., Watanabe T. et al. (1996) TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc. Natl. Acad. Sci. USA **93:** 9437–9442
243 Ishida T., Mizushima S., Azuma S., Kobayashi N., Tojo T., Suzuki K. et al. (1996) Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. **271:** 28745–28748
244 Pullen S. S., Miller H. G., Everdeen D. S., Dang T. T. A., Crute J. J. and Kehry M. R. (1998) CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry **37:** 11836–11845
245 Nakano H., Oshima H., Chung W., Williams-Abbott L., Ware C. F., Yagita H. et al. (1996) TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J. Biol. Chem. **271:** 14661–14664
246 Pullen S. S., Labadia M. E., Ingraham R. H., McWhirter S. M., Everdeen D. S., Alber T. et al. (1999) High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry **38:** 10168–10177
247 Sutherland C. L., Krebs D. L. and Gold M. R. (1999) An 11-amino acid seq1uence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinse-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest. J. Immunol. **162:** 4720–4730
248 Dadgostar H. and Cheng G. (1998) An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activatin but is dispensable for c-Jun N-terminal kinase signaling. J. Biol. Chem. **273:** 24775–24780
249 Grammer A. C., Swantek J. L., McFarland R. D., Miura Y., Geppert T. and Lipsky P. E. (1998) TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J. Immunol. **161:** 1183–1193
250 Tsukamoto N., Kobayashi N., Azuma S., Yamamoto T. and Inoue J. (1999) Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. Proc. Natl. Acad. Sci. USA **96:** 1234–1239
251 Pullen S. S., Dang T. T., Crute J. J. and Kehry M. R. (1999) CD40 signaling through tumor necrosis factor reptor-associated factors (TRAFs): binding site specificity and activation of downstream pathways by distinct trafs. J. Biol. Chem. **274:** 14246–14254
252 Lee H. H., Dempsey P. W., Parks T. P., Zhu X., Baltimore D. and Cheng G. (1999) Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc. Natl. Acad. Sci. USA **96:** 1421–1426
253 McCarthy J. V., Ni J. and Dixit V. M. (1998) RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J. Biol. Chem. **273:** 16968–16975
254 Galibert L., Tometsko M. E., Anderson D. M., Cosman D. and Dougall W. C. (1998) The involement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J. Biol. Chem. **273:** 34120–34127
255 Darnell J. E. Jr, Kerr I. M. and Stark G. R. (1994) Jak-STAT pathways and transcriptional action in response to IFNs and other extracellular signaling proteins. Science **264:** 1415–1421
256 Karras J. G., Wang Z., Huo L., Frank D. A. and Rothstein T. L. (1997) Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J. Immunol. **159:** 4350–4355
257 Tortolani P. J., Lal B. K., Riva A., Johnston J. A., Chen Y. Q., Reaman G. H. et al. (1995) Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J. Immunol. **155:** 5220–5226
258 Jabara H. H., Buckley R. H., Roberts J. L., Lefranc G., Loiselet J., Khalil G. et al. (1998) Role of JAK3 in CD40-mediated signaling. Blood **92:** 2435–2440
259 Worm M. M., Tsytsykova A. and Geha R. S. (1998) CD40 ligation and IL-4 use different mechanisms of transcriptional activation of the human lymphotoxin alpha promoter in B cells. Eur. J. Immunol. **28:** 901–906
260 Schaffer A., Cerutti A., Shah S., Zan H. and Casali P. (1999) The evolutionarily conserved sequence upstream of the human Ig heavy chain S gamma 3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF-kappa B and STAT-6 binding sites. J. Immunol. **162:** 5327–5336
261 Lalmanach-Girard A. C., Chiles T. C., Parker D. C. and Rothstein T. L. (1993) T cell-dependent induction of NF-kappa B in B cells. J. Exp. Med. **177:** 1215–1219
262 Berberich I., Shu G. L. and Clark E. A. (1994) Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J. Immunol. **153:** 4357–4366
263 Kosaka Y., Calderhead D. M., Manning E. M., Hambor J. E., Black A., Geleziunas R. et al. (1999) Activation and regulation of the IkappaB kinase in human B ells by CD40 signaling. Eur. J. Immunol. **29:** 1353–1362
264 Hornung M., Lindemann D., Kraus C., Peters A. and Berberich I. (1998) The CD40 TRAF family member interacting motif carries the information to rescue WEHI 231 cells from anti-IgM-induced growth arrest. Eur. J. Immunol. **28:** 3812–3823
265 Jeppson J. D., Patel H. R., Sakata N., Domenico J., Terada N. and Gelfand E. W. (1998) Requirement for dual signals by anti-CD40 and IL-4 for the induction of nuclear factor-kappa B, IL-6, and IgE in human B lymphocytes. J. Immunol. **161:** 1738–1742
266 Huo L. and Rothstein T. L. (1995) Receptor-specific induction of individual AP-1 components in B lymphocytes. J. Immunol. **154:** 3300–3309
267 Choi M. S., Brines R. D., Holman M. J. and Klaus G. G. (1994) Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with Il-4. Immunity **1:** 179–187
268 Klaus G. G., Choi M. S. and Holman M. (1994) Properties of mouse CD40: ligation of CD40 activates B cells via a Ca(+ +)-dependent, FK506-sensitive pathway. Eur. J. Immunol. **24:** 3229–3232
269 Lam E. W., Choi M. S., Sman J. van der, Burbidge S. A. and Klaus G. G. (1998) Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. J. Biol. Chem. **273:** 10051–10057
270 Lee J. R. and Koretzky G. A. (1998) Production of reactive oxygen intermediates following CD40 ligation correlates with c-Jun N-terminal kinase activation and IL-6 secretion in murine B lymphocytes. Eur. J. Immunol. **28:** 4188–4197
271 Hess S., Rensing-Ehl A., Schwabe R., Bufler P. and Engelmann H. (1995) CD40 function in nonhematopoietic cells: nuclear factor kappa B mobilization and induction of IL-6 production. J. Immunol. **155:** 4588–4595

272 Eliopoulos A. G., Dawson C. W., Mosialos G., Floettmann J. E., Rowe M., Armitage R. J. et al. (1996) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene **13:** 2243–2254
273 Klaus S. J., Berberich I., Shu G. and Clark E. A. (1994) CD40 and its ligand in the regulation of humoral immunity. Semin. Immunol. **6:** 279–286
274 Durie F. H., Foy T. M., Masters S. R., Laman J. D. and Noelle R. J. (1994) The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today **15:** 406–411
275 Hollenbaugh D., Ochs H. D., Noelle R. J., Ledbetter J. A. and Aruffo A. (1994) The role of CD40 and its ligand in the regulation of the immune response. Immunol. Rev. **138:** 23–37
276 Laman J. D., Claassen E. and Noelle R. J. (1996) Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. **16:** 59–108
277 Foy T. M., Aruffo A., Bajorath J., Buhlmann J. E. and Noelle R. J. (1996) Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. **14:** 591–617
278 Kooten C. van and Banchereau J. (1997) Functional role of CD40 and its ligand. Int. Arch. Allergy Immunol. **113:** 393–399
279 Lipsky P. E., Attrep J. F., Grammer A. C., McIlraith M. J. and Nishioka Y. (1997) Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function. Ann. NY Acad. Sci. **815:** 372–383
280 Barrett T. B., Shu G. and Clark E. A. (1991) CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J. Immunol. **146:** 1722–1729
281 Flores-Romo L., Estoppey D. and Bacon K. B. (1993) Anti-CD40 antibody stimulates the VLA-4-dependent adhesion of normal and LFA-1-deficient B cells to endothelium. Immunology **79:** 445–451
282 Cerutti A., Schaffer A., Shah S., Zan H., Liou H. C., Goodwin R. G. et al. (1998) CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity **9:** 247–256
283 Liu Y. J., Barthelemy C., Bouteiller O. de, Arpin C., Durand I. and Banchereau J. (1995) Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity **2:** 239–248
284 Ranheim E. A. and Kipps T. J. (1993) Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. **177:** 925–935
285 Yellin M. J., Sinning J., Covey L. R., Sherman W., Lee J. J., Glickman-Nir E. et al. (1994) T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J. Immunol. **153:** 666–674
286 Garrone P., Neidhardt E. M., Garcia E., Galibert L., Kooten C. van and Banchereau J. (1995) Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. **182:** 1265–1273
287 Schattner E. J., Elkon K. B., Yoo D. H., Tumang J., Krammer P. H., Crow M. K. et al. (1995) CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J. Exp. Med. **182:** 1557–1565
288 Zan H., Cerutti A., Dramitinos P., Schaffer A. and Casali P. (1998) CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependent direct S mu → S alpha and sequential S mu → gamma, S gamma → alpha DNA recombination. J. Immunol. **161:** 5217–5225
289 Burdin N., Peronne C., Banchereau J. and Rousset F. (1993) Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J. Exp. Med. **177:** 295–304
290 Boussiotis V. A., Nadler L. M., Strominger J. L. and Goldfeld A. E. (1994) Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc. Natl. Acad. Sci. USA **91:** 7007–7011
291 Itoh M., Uchimura K., Hayakawa N., Makino M., Hayashi R., Nagata M. et al. (1998) surface expression and release of soluble forms of CD8 and CD23 in CD40- and IL-4-activated mononuclear cells from patients with Graves' disease (GD). Clin. Exp. Immunol. **113:** 309–314
292 Defrance T., Vanbervliet B., Durand I., Briolay J. and Banchereau J. (1992) Proliferation and differentiation of human CD5 + and CD5 − B cell subsets activated through their antigen receptors or CD40 antigens. Eur. J. Immunol. **22:** 2831–2839
293 Arpin C., Dechanet J., Kooten C. van, Merville P., Grouard G., Briere F. et al. (1995) Generation of memory B cells and plasma cells in vitro. Science **268:** 720–722
294 Lane P., Brocker T., Hubele S., Padovan E., Lanzavecchia A. and McConnell F. (1993) soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cell in T cell-dependent activation. J. Exp. Med. **177:** 1209–1213
295 Snapper C. M., Kehry M. R., Castle B. E. and Mond J. J. (1995) Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells: a redefinition of the TI-2 vs T cell-dependent antigen dichotomy. J. Immunol. **154:** 1177–1187
296 Banchereau J. and Rousset F. (1991) Growing human B lymphocytes in the CD40 system. Nature **353:** 678–679
297 Rousset F., Garcia E. and Banchereau J. (1991) Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J. Exp. Med. **173:** 705–710
298 Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D. H. et al. (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA **89:** 1890–1893
299 Spriggs M. K., Armitage R. J., Strockbine L., Clifford K. N., Macduff B. M., Sato T. A. et al. (1992) Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J. Exp. Med. **176:** 1543–1550
300 Brass U., Tretter T., Schneller F., Schuler M., Huber C. and Peschel C. (1999) IFN-alpha stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro. J. Interferon Cytokine Res. **19:** 335–343
301 Horwitz B. H., Zelazowski P., Shen Y., Wolcott K. M., Scott M. L., Baltimore D. et al. (1999) The p65 subunit of NF-kappa B is redundant with p50 during B cell proliferative responses, and is required for germline CH transcription and class switching to IgG3. J. Immunol. **162:** 1941–1946
302 Fruman D. A., Snapper S. B., Yballe C. M., Davidson L., Yu J. Y., Alt F. W. et al. (1999) Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science **283:** 393–397
303 Schultz C. L., Rothman P., Kuhn R., Kehry M., Muller W., Rajewsky K. et al. (1992) T helper cell membranes promote IL-4-independent expression of germ-line C gamma 1 transcripts in B cells. J. Immunol. **149:** 60–64
304 Hodgkin P. D., Castle B. E. and Kehry M. R. (1994) B cell differentiation induced by helper T cell membranes: evidence for sequential isotype switching and a requirement for lymphokines during proliferation. Eur. J. Immunol. **24:** 239–246
305 Ballantyne J., Henry D. L., Muller J. R., Briere F., Snapper C. M., Kehry M. et al. (1998) Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implications for the control of CH gene switch recombination. J. Immunol. **161:** 1336–1347

306 Splawski J. B., Fu S. M. and Lipshy P. E. (1993) Immunoregulatory role of D40 in human B cell differentiation. J. Immunol. **150:** 1276–1285
307 Defrance T., Vanbervliet B., Briere F., Durand I., Rousset F. and Banchereau J. (1992) Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activate naïve human B cells to secrete immunoglobulin A. J. Exp. Med. **175:** 671–682
308 Briere F., Servet-Delpart C., Bridon J. M., Saint-Remy J. M. and Banchereau J. (1994) Human interleukin 10 induces naïve surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J. Exp. Med. **179:** 757–762
309 Fujieda S., Zhang K. and Saxon A. (1995) IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: switching to gamma 1, gamma 3, and gamma 4, but not gamma 2. J. Immunol. **155:** 2318–2328
310 Armitage R. J., Macduff B. M., Spriggs M. K. and Fanslow W. C. (1993) Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J. Immunol. **150:** 3671–3680
311 Noelle R. J., Shepherd D. M. and Fell H. P. (1992) Cognate interaction between T helper cells and B cells. VII. Role of contact and lymphokines in the expression of germ-line and mature gamma 1 Transcripts. J. Immunol. **149:** 1164–1169
312 Maliszewski C. R., Grabstein K., Fanslow W. C., Armitage R., Spriggs M. K. and Sato T. A. (1993) Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines. Eur. J. Immunol. **23:** 1044–1049
313 Vercelli D., Jabara H. H., Arai K., Yokota T. and Geha R. S. (1989) Endogenous interleukin 6 plays an obligatory role in interleukin 4-dependent human IgE synthesis. Eur. J. Immunol. **19:** 1419–1424
314 Gascan H., Gauchat J. F., Roncarolo M. G., Yssel H., Spits H. and Vries J. E. de (1991) Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J. Exp. Med. **173:** 747–750
315 Gauchat J. F., Lebman D. A., Coffman R. L., Gascan H. and Vries J. E. de (1990) Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J. Exp. Med. **172:** 463–473
316 Jabara H. H., Loh R., Ramesh N., Vercelli D. and Geha R. S. (1993) Sequential switching from mu to epsilon via gamma 4 in human B cells stimulated with IL-4 and hydrocortisone. J. Immunol. **151:** 4528–4533
317 Punnonen J., Yssel H. and de Vries J. E. (1997) The relative contribution of IL-4 and hydrocortisone. J. Immunol. **151:** 4528–4533
318 Ichiki T., Takahashi W. and Watanabe T. (1993) Regulation of the expression of human C epsilon germline transcript: identification of a novel IL-4 responsive element. J. Immunol. **150:** 5408–5417
319 Xu L. and Rothman P. (1994) IFN-gamma represses epsilon germline transcription and subsequently down-regulates switch recombination to epsilon. Int. Immunol. **6:** 515–521
320 Gauchat J. F., Gascan H., Waal Malefyt R. de and Vries J. E. de (1992) Regulation of germ-line epsilon transcription and induction of epsilon switching in cloned EBV-transformed and malignant human B cell lines by cytokines and CD4+ T cells. J. Immunol. **148:** 2291–2299
321 Pene J., Rousset F., Briere F., Chretien I., Paliard X., Banchereau J. et al. (1988) IgE production by normal human B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-gamma. J. Immunol. **141:** 1218–1224
322 Worm M., Krah J. M., Manz R. A. and Henz B. M. (1998) Retinoic acid inhibits CD40+interleukin-4-mediated IgE production in vitro. Blood **92:** 1713–1720
323 Bjorck P., Larsson S., Andang M., Ahrlund-Richter L. and Paulie S. (1998) IL-6 antisense oligonucleotides inhibit IgE production in IL-4 and anti-CD40-stimulated human B-lymphocytes. Immunol. Lett. **61:** 1–5
324 Iciek L. A., Delphin S. A. and Stavenezer J. (1997) CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction. J. Immunol. **158:** 4769–4779
325 Thienes C. P., De Monte L., Monticelli S., Busslinger M., Gould H. J. and Verceli D. (1997) The transcription factor B cell-specific activator protein (BSAP) enhances both IL-4- and CD40-mediated activation of the human epsilon germline promoter. J. Immunol. **158:** 5874–5882
326 MacLennan I. C. (1994) Germinal centers. Annu. Rev. Immunol. **12:** 117–139
327 Pound J. D. and Gordon J. (1997) Maintenance of human germinal center B cells in vitro. Blood **89:** 919–928
328 Grat D., Bergthorsdottir S., Essen D. van, Wykes M., Poudrier J. and Siepmann K. (1997) Observations on memory B-cell development. Semin. Immunol. **9:** 249–254
329 Kindler V. and Zubler R. H. (1997) Memory, but not naïve, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10, and IL-3. J. Immunol. **159:** 2085–2090
330 Blott M. H., Marshall J. D., DeKruyff R. H. and Umetsu D. T. (1996) Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis. J. Immunol. **156:** 3133–3140
331 Essen D. van, Kikutani H. and Gray D. (1995) CD40 ligand-transduces co-stimulation of T cells in the development of helper function. Nature **378:** 620–623
332 Worm M., Ebermayer K. and Henz B. (1998) Lymphotoxin-alpha is an important autocrine factor for CD40 interleukin-4-mediated B-cell activation in normal and atopic donors. Immunology **94:** 395–402
333 Kindler V., Mattes T., Jeannin P. and Zubler R. H. (1995) Interleukin-2 secretion by human B lymphocytes occurs as a late event and requires additional stimulation after CD40 cross-linking. Eur. J. Immunol. **25:** 1239–1243
334 Worm M. and Geha R. S. (1995) Activation of tumor necrosis factor-alpha and lymphotoxin-alpha via anti-CD40 in human B cells. Int. Arch. Allergy Immunol. **107:** 368–369
335 Park S. M., Kim H. S., Choe J. and Lee T. H. (1999) Differential induction of cytokine genes and activation of mitogen-activated protein kinase family by soluble CD40 ligand and TNF in a human follicular dendritic cell line. J. Immunol. **163:** 631–638
336 Urashima M., Chauhan D., Uchiyama H., Freeman G. J. and Anderson K. C. (1995) CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood **85:** 1903–1912
337 Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E. et al. (1996) High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. **184:** 741–746
338 Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A. and Alber G. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin 12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. **184:** 747–752
339 Yoshimoto T., Nagase H., Ishida T., Inoue J. and Nariuchi H. (1997) Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB. Eur. J. Immunol. **27:** 3461–3470
340 Kelsall B. L., Stuber E., Neurath M. and Strober W. (1996) Interleukin-12 production by dendritic cell: the role of CD40-CD40L interactions in Th1 T-cell responses. Ann. NY Acad. Sci. **795:** 116–126
341 McDyer J. F., Goletz T. J., Thomas E., June C. H. and Seder R. A. (1998) CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. J. Immunol. **160:** 1701–1707

342 Zhou P. and Seder R. A. (1998) CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with *Histoplasma capsulatum*. J. Exp. Med. **187:** 1315–1324
343 Kooten C. van, Gerritsma J. S., Paape M. E., Es L. A. van, Banchereau J. and Daha M. R. (1997) Possible role CD40-CD40L in the regulation of interstitial in the kidney. Kidney Int. **51:** 711–721
344 Kornbluth R. S., Kee K. and Richman D. D. (1998) CD40 ligand (CD154) stimulation of macrophages to produce HIV-1 suppressive beta-chemokines. Proc. Natl. Acad. Sci. USA **95:** 5205–5210
345 McDyer J. F., Dybul M., Goletz T. J., Kinter A. L., Thomas E. K., Berzofsky J. A. et al. (1999) Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms. J. Immunol. **162:** 3711–3717
346 Schaniel C., Pardali E., Sallusto F., Speletas M., Ruedl C., Shimizu T. et al. (1998) Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J. Exp. Med. **188:** 451–463
347 Deckers J. G., De Haij S., Woude F. J. van der, Kooij S. W. van der, Daha M. R. and Kooten C. van (1998) IL-4 and IL13 augment cytokine-and CD40-induced RANTES production by human renal tubular epithelial cells in vitro. J. Am. Soc. Nephrol **9:** 1187–1193
348 Nardelli B., Morahan D. K., Bong G. W., Semenuk M. A., Kreider B. L. and Garotta G. (1999) Demdritic cells and MPIF-1 chemotactic activity and inhibition of endogenous chemokine production by IFN-gamma and CD40 ligation. J. Leukoc. Bol. **65:** 822–828
349 Sozzani S., Allavena P., Amico G. D., Luini W., Bianchi G., Kataura M. et al. (1998) Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. **161:** 1083–1086
350 Sallusto F., Schaerli P., Loetscher P., Schaniel C., Lenig D., Mackay C. R. et al. (1998) Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. **28:** 2760–2769
351 Katada Y., Tanaka T., Ochi H., Aitani M., Yokota A., Kikytani H. et al. (1996) B cell-B cell interaction through intercellular adhesion molecule-1 and lymphocyte functional antigen-1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin-4 and anti-CD40 antibody. Eur. J. Immunol. **26:** 192–200
352 Karmann K., Min W., Fanslow W. C. and Pober J. S. (1996) Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. J. Exp. Med. **184:** 173–182
353 Gruss H. J., Scheffrahn I., Hubinger G., Duyster J. and Hermann F. (1996) The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia **10:** 829–835
354 Pellat-Deceunynck C., Amiot M., Robillard N., Wijdenes J. and Bataille R. (1996) CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res. **56:** 1909–1916
355 Teoh G., Urashima M., Greenfield E. A., Nguyen K. A., Lee J. F., Chauhan D. et al. (1998) The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J. Clin. Invest. **101:** 1379–1388
356 Mach F., Schonbeck U., Fabunmi R. P., Murphy C., Atkinson E., Bonnefoy J. Y. et al. (1999) T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am. J. Pathol. **154:** 229–238
357 Sukhova G. K., Schonbeck U., Rabkin E., Schoen F. J., Poole A. R., Billinghurst R. C. et al. (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation **99:** 2503–2509
358 Laman J. D., De boer M. and 't Hart B. A. (1998) CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Dev. Immunol. **6:** 215–222
359 Mach F., Schönbeck U. and Libby P. (1998) CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis **137** (Suppl)**:** S89–S95
360 Smariga P. E. and Maynard J. R. (1982) Platelet effects on tissue factor and fibrinolytic inhibition of cultured human fibroblasts and vascular cells. Blood **60:** 140–147
361 Gregory S. A. and Edgington T. S. (1985) Tissue factor induction in human monocytes: two distinct mechanisms displayed by different alloantigen-responsive T cell clones. J. Clin. Invest. **76:** 2440–2445
362 Pradier O., Willems F., Abramowicz D., Schandene L., Boer M. de, Thielemans K. et al. (1996) CD40 engagement induces monocyte procoagulant activity through an interleukin-10 resistant pathway. Eur. J. Immunol. **26:** 3048–3054
363 Miller D. L., Yaron R. and Yellin M. J. (1998) CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc. Biol. **63:** 373–379
364 Zhou L., Stordeur P., Lavareille A. de, Thielemans K., Capel P., Goldman M. et al. (1998) CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb. Haemost. **79:** 1025–1028
365 Adawi A., Zhang Y., Baggs R., Finkelstein J. and Phipps R. P. (1998) Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. Am. J. Pathol. **152:** 651–657
366 Schönbeck U., Sukhova G. K., Graber P., Coulter S. and Libby P. (1999) Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. **155:** 1281–1291
367 Tian L., Noelle R. J. and Lawrence D. A. (1995) Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur. J. Immunol. **25:** 306–309
368 Stout R. D., Suttles J., Xu J., Grewal I. S. and Flavell R. A. (1996) Imparied T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. **156:** 8–11
369 Lu L., Bonham C. A., Chambers F. G., Watkins S. C., Hoffman R. A., Simmons R. L. et al. (1996) Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J. Immunol. **157:** 3577–3586
370 Liu Y. J., Joshua D. E., Williams G. T., Smith C. A., Gordon J. and MacLennan I. C. (1989) Mechanism of antigen-driven selection in germinal centres. Nature **342:** 929–931
371 Rothstein T. L., Wang J. K., Panka D. J., Foote L. C., Wang Z., Stanger B. et al. (1995) Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature **374:** 163–165
372 Valentine M. A. and Licciardi K. A. (1992) Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40. Eur. J. Immunol. **22:** 3141–3148
373 Tsubata T., Wu J. and Honjo T. (1993) B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature **364:** 645–648
374 Lederman S., Yellin M. J., Cleary A. M., Pernis A., Inghirami G., Cohn L. E. et al. (1994) T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombinatioon and rescues B cells from programmed cell death. J. Immunol. **152:** 2163–2171
375 Parry S. L., Hasbold J., Holman M. and Klaus G. G. (1994) Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulated with IL-4 and anti-CD40. J. Immunol. **152:** 2821–2829
376 Cherney B. W., Bhatia K. and Tosato G. (1994) A role for deregulated c-Myc expression in apoptosis of Epstein-Barr

virus-immortalized B cells. Proc. Natl. Acad. Sci. USA **91:** 12967–12971
377 Merino R., Grillot D. A., Simonian P. L., Muthukkumar S., Fanslow W. C., Bondada S. et al. (1995) Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells: dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J. Immunol. **155:** 3830–3838
378 Schauer S. L., Wang Z., Sonenshein G. E. and Rothstein T. L. (1996) Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins. J. Immunol. **157:** 81–86
379 Kaptein J. S., Lin C. K. E., Wang C. L., Nguyen T. T., Kalunta C. I., Park E. et al. (1996) Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis. J. Biol. Chem. **271:** 18875–18884
380 Sonenshein G. E. (1997) Down-modulation of c-myc expression induces apoptosis of B lymphocyte models of tolerance via clonal deletion. J. Immunol. **158:** 1994–1997
381 Akifusa S., Ohguchi M., Koseki T., Nara K., Semba I., Yamato K. et al. (1998) Increase in Bcl-2 level promoted by CD40 ligation correlates with inhibition of B Cell apoptosis induced by vacular type H(+)-ATPase inhibitor. Exp. Cell Res. **238:** 82–89
382 Merville P., Dechanet J., Desmouliere A., Durand I., Bouteiller O. de, Garrone P. et al. (1996) Bcl-2 + tonsillar plasma cells are rescued from apoptosis by bone marow fibroblasts. J. Exp. Med. **183:** 227–236
383 Younes A., Snell V., Consoli U., Clodi K., Zhao S., Palmer J. L. et al. (1998) Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br. J. Haematol. **100:** 135–141
384 Holder M.J., Wang H., Milner A. E., Casamayor M., Armitage R., Spriggs M. K. et al. (1993) Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction. Eur. J. Immunol. **23:** 2368–2371
385 Wang H., Grand R. J., Milner A. E., Armitage R. J., Gordon J. and Gregory C. D. (1996) Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein. Oncogene **13:** 373–379
386 Nakayama K., Dustin L. B. and Loh D. Y. (1995) T-B cell interaction inhibits spontaneous apoptosis of mature lymphocytes in Bcl-2 deficient mice. J. Immunol. **182:** 1101–1109
387 Grillot D. A., Merino R., Pena J. C., Fanslow W. C., Finkelman F. D., Thompson C. B. et al. (1996) Bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J. Exp. Med. **183:** 381–391
388 Tuscano J. M., Druey K. M., Riva A., Pena J., Thompson C. B. and Kehrl J. H. (1996) Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood **88:** 1359–1364
389 Ishida T., Kobayashi N., Tojo T., Ishida S., Yamamoto T. and Inoue J. (1995) CD40 signaling-mediated induction of Bcl-XL, Cdk4, and Cdk6: implication of their cooperation in selective B cell growth. J. Immunol. **155:** 5527–5535
390 Choi M. S., Holmann M., Atkins C. J. and Klaus G. G. (1996) Expression of blc-x during mouse B cell differentiation and following activation by various stimuli. Eur. J. Immunol. **26:** 676–682
391 Martinez-Valdez H., Guret C., Bouteiller O. de, Fugier I., Banchereau J. and Liu Y. J. (1996) Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. J. Exp. Med. **183:** 971–977
392 Zhang X., Li L., Choe J., Krajewski S., Reed J. C., Thompson C. et al. (1996) Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Cell. Immunol. **173:** 149–154
393 Koizumi T., Wang J., Suzuki Y., Masuda K. and Watanabe T. (1996) Regulation of bcl-xL expression and Fas susceptibility in mouse B cells by CD40 ligation, surface IgM crosslinking and IL-4. Mol. Immunol. **33:** 1247–1253
394 Fang W., Nath K. A., Mackey M. F., Noelle R. J., Mueller D. L. and Behrens T. W. (1997) CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Am. J. Physiol. **272:** C950–956
395 Ghia P., Boussiotis V. A., Schultze J. L., Cardoso A. A., Dorfman D. M., Gribben J. G. et al. (1998) Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood **91:** 244–251
396 Wang Z., Karras J. G., Howard R. G. and Rothstein T. L. (1995) Induction of bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells. J. Immunol. **155:** 3722–3725
397 An S. and Knox K. A. (1996) Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP. FEBS Lett. **386:** 115–122
398 An S., Yap D. and Knox K. A. (1997) Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells. Cell. Immunol. **181:** 139–152
399 Cleary A. M., Fortune S. M., Yellin M. J., Chess L. and Lederman S. (1995) Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J. Immunol. **155:** 3329–3337
400 Rathmell J. C., Cooke M. P., Ho W. Y., Grein J., Townsend S. E., Davis M. M. et al. (1995) CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4 + T cells. Nature **376:** 181–184
401 Lagresle C., Mondiere P., Bella C., Krammer P. H. and Defrance T. (1996) Concurrent engagement of CD40 and the antigen receptor protects naïve and memory human B cells from APO-1/Fas-mediated apoptosis. J. Exp. Med. **183:** 1377–1388
402 Nakanishi K., Matsui K., Kashiwamura S., Nishioka Y., Nomura J., Nishimura Y. et al. (1996) IL-4 and anti-CD40 protect against Fas-mediated B cell apoptosis and induce B cell growth and differentiation. Int. Immunol. **8:** 791–798
403 Heath A. W., Chang R., Harada N., Santos-Argumedo L., Gordon J., Hannum C. et al. (1993) Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell. Immunol. **152:** 468–480
404 Yamashita Y., Miyake K., Miura Y., Kaneko Y., Yagita H., Suda T. et al. (1996) Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor coligation. J. Exp. Med. **184:** 113–120
405 Choe J., Kim H. S., Zhang X., Armitage R. J. and Choi Y. S. (1996) Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells: anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. J. Immunol. **157:** 1006–1016
406 Billian G., Mondiere P., Berard M., Bella C. and Defrance T. (1997) Antigen receptor-induced apoptosis of human germinal center B cells is targeted to a centrocytic subset. Eur. J. Immunol. **27:** 405–414
407 Suttles J., Evans M., Miller R. W., Poe J. C., Stout R. D. and Wahl L. M. (1996) T cell rescue of monocytes from apoptosis: role of the CD40-CD40L interaction and requirement for CD40-mediated induction of protein tyrosine kinase activity. J. Leukoc. Biol. **60:** 651–657
408 Bjorck P., Banchereau J. and Flores-Romo L. (1997) CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int. Immunol. **9:** 365–372
409 Hess S., Gottfried E., Smola H., Grunwald U., Schuchmann M. and Engelmann H. (1998) CD40 induces resistance to

TNF-mediated apoptosis in a fibroblast cell line. Eur. J. Immunol. **28:** 3594–3604
410 Ruan Y., Rabizadeh S., Camerini D. and Bredesen D. E. (1997) Expression of CD40 induces neural apoptosis. J. Neurosci. Res. **50:** 383–390
411 Hess S. and Engelmann H. (1996) A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med. **183:** 159–167
412 Wang D., Freeman G. J., Levine H., Ritz J. and Robertson M. J. (1997) Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol. **97:** 409–417
413 Koppi T. A., Tough-Bement T., Lewinsohn D. M., Lynch D. H. and Alderson M. R. (1997) CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. Eur. J. Immunol. **27:** 3161–3165
414 Walker A., Taylor S. T., Hickman J. A. and Drive C. (1997) Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Res. **57:** 1939–1945
415 Voorzanger-Rousselot N., Favrot M. and Blay J. Y. (1998) Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood **92:** 3381–3387
416 Xerri L., Bouabdallah R., Devilard E., Hassoun J., Stoppa A. M. and Brig F. (1998) Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br. J. Cancer **78:** 225–232
417 Laytragoon-Lewin N., Duhony E., Bai X. F. and Mellstedt H. (1998) Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells. Eur. J. Haematol. **61:** 266–271
418 Hirano A., Longo D. L., Taub D. D., Ferris D. K., Young L. S., Eliopoulos A. G. et al. (1999) Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood **93:** 2999–3007
419 Fujieda S., Sugimoto C., Seki M., Sunaga H. and Saito H. (1998) CD40 stimulation inhibits cell growth and Fas-mediated apoptosis in a thyroid cancer cell line. Oncol. Res. **10:** 433–439
420 Esche C., Gambotto A., Satoh Y., Gerein V., Robbins P. D., Watkins S. C. et al. (1999) CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur. J. Immunol. **29:** 2148–2155
421 Lomo J., Blomhoff H. K., Jacobsen S. E., Krajewski S., Reed J. C. and Smeland E. B. (1997) Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood **89:** 4415–4424
422 Poe J. C., Wagner D. H. Jr, Miller R. W., Stout R. D. and Suttles J. (1997) IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1 beta synthesis and rescue from apoptosis. J. Immunol. **159:** 846–852
423 Ning Z. Q., Norton J. D., Li J. and Murphy J. J. (1996) Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36. Eur. J. Immunol. **26:** 2356–2363
424 Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S. et al. (1993) The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell **72:** 291–300
425 Allen R. C., Armitage R. J., Conley M. E., Rosenblatt H., Jenkins N. A., Copeland N. G. et al. (1993) CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science **259:** 990–993
426 Hollenbaugh D., Wu L. H., Ochs H. D., Nonoyama S., Grosmaire L. S., Ledbetter J. A. et al. (1994) The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1. J. Clin. Invest. **94:** 616–622
427 DiSanto J. P., Bonnefoy J.-Y., Gauchat J. F., Fischer A. and Saint Basile G. de (1993) CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature **361:** 541–543
428 Fuleihan R., Ramesh N., Loh R., Jabara H., Rosen R. S., Chatila T. et al. (1993) Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc. Natl. Acad. Sci. USA **90:** 2170–2173
429 Korthauer U., Graf D., Mages W., Briere F., Padayachee M., Malcolm S. et al. (1993) Defective expression of T-cell CD40 ligand causes X-linked immunodefiency with hyper-IgM. Nature **361:** 539–541
430 Notarangelo L. D. and Peitsch M. C. (1996) CD401base: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol. Today **17:** 511–516
431 Katz F., Hinshelwood S., Rutland P., Jones A., Kinnon C. and Morgan G. (1996) Mutation analysis in CD40 ligand deficiency leading to X-linked hypogammaglobulinemia with hyper IgM syndrome. Hum. Mutat. **8:** 223–228
432 Dezso D., Orth U., Heilbronner H. and Gal A. (1996) A novel splice-site mutation in the CD40L gene in a patient with X-linked hyper-IgM syndrome. Hum. Mutat. **7:** 181–182
433 Seyama K., Nonoyama S., Gangsaas I., Hollenbaugh D., Pabst H. F., Aruffo A. et al. (1998) Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood **92:** 2421–2434
434 Seyama K., Osborne W. R. and Ochs H. D. (1999) CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand. J. Biol. Chem. **274:** 11310–11320
435 Conley M. E., Larche M., Bonagura V. R., Lawton 3rd A. R., Buckley R. H., Fu S. M. et al. (1994) Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J. Clin. Invest. **94:** 1404–1409
436 Xu J., Foy T. M., Laman J. D., Elliott E. A., Dunn J. J., Waldschmidt T. J. et al. (1994) Mice deficient for the CD40 ligand. Immunity **1:** 423–431
437 Renshaw B. R., Fanslow 3rd W. C., Armitage R. J., Campbell K. A., Liggitt D., Wright B. et al. (1994) Humoral immune responses in CD40 ligand-deficient mice. J. Exp. Med. **180:** 1889–1900
438 Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S. et al. (1994) The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity **1:** 167–178
439 Agy M. B., Foy K., Gale M. J., Benveniste R. E., Clark E. A. and Katze M. G. (1991) Viral and cellular gene expression in CD4+ human lymphoid cell lines infected by the simian immunodeficiency virus, SIV/Mne. Virology **183:** 170–180
440 Macchia D., Almerigogna F., Parronchi P., Ravina A., Maggi E. and Romagnani S. (1993) Membrane tumour necrosis factor-alpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature **363:** 464–466
441 Chirmule N., McCloskey T. W., Hu R., Kalyanaraman V. S. and Pahwa S. (1995) HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71). J. Immunol. **155:** 917–924
442 Gras G., Legendre C., Krzysiek R., Dormont D., Galanaud P. and Richard Y. (1996) CD40/CD40L interactions and cytokines regulate HIV replication in B cells in vitro. Virology **220:** 309–319
443 Pinchuk L. M., Polacino P. S., Agy M. B., Klaus S. J. and Clark E. A. (1994) The role of CD40 and CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity **1:** 317–325
444 Poulin L., Paquette N., Moir S., Lapointe R. and Darveau A. (1994) Productive infection of normal CD40-activated human B lymphocytes by HIV-1. Aids **8:** 1539–1544
445 Ruby J., Bluethmann H., Aguet M. and Ramshaw I. A. (1995) CD40 ligand has potent antiviral activity. Nat. Med. **1:** 437–441

446 Borrow P., Tishon A., Lee S., Xu J., Grewal I. S., Oldstone M. B. et al. (1996) CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J. Exp. Med. **183:** 2129–2142
447 Yang Y. and Wilson J. M. (1996) CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science **273:** 1862–1864
448 Grewal I. S., Borrow P., Pamer E. G., Oldstone M. B. and Flavell R. A. (1997) The CD40-CD154 system in anti-infective host defense. Curr. Opin. Immunol. **9:** 491–497
449 Subauste C. S., Wessendarp M., Sorensen R. U. and Leiva L. E. (1999) CD40-CD40 ligand interaction is central to cell-mediated immunity against *Toxoplasma gondii*: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. J. Immunol. **162:** 6690–6700
450 Kamanaka M., Yu P., Yasui T., Yoshida K., Kawabe T., Horii T. et al. (1996) Protective role of CD40 in *Leishmania major* infection at two distinct phases of cell-mediated immunity. Immunity **4:** 275–281
451 Soong L., Xu J. C., Grewal I. S., Kima P., Sun J., Longley B. J. Jr et al. (1996) Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to *Leishmania amazonensis* infection. Immunity **4:** 263–273
452 Campbell K. A., Ovendale P. J., Kennedy M. K., Fanslow W. C., Reed S. G. and Maliszewski C. R. (1996) CD40 ligand is required for protective cell-mediated immunity to *Leishmania major*. Immunity **4:** 283–289
453 Ferlin W. G., Weid T. von der, Cottrez F., Ferrick D. A., Coffman R. L. and Howard M. C. (1998) The induction of a protective response in *Leishmania major*-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. **28:** 525–531
454 Fikrig E., Barthold S. W., Chen M., Grewal I. S., Craft J. and Flavell R. A. (1996) Protective antibodies in murine Lyme disease arise independently of CD40 ligand. J. Immunol. **157:** 1–3
455 Lu P., Urban J. F., Zhou X. D., Chen S. J., Madden K., Moorman M. et al. (1996) CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production. J. Immunol. **156:** 3327–3333
456 Wiley J. A. and Harmsen A. G. (1995) CD40 ligand is required for resolution of *Pneumocystis carinii* pneumonia in mice. J. Immunol. **155:** 3525–3529
457 Heinzel F. P., Rerko R. M. and Hujer A. M. (1998) Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity. Cell. Immunol. **184:** 129–142
458 Gurunathan S., Irvine K. R., Wu C. Y., Cohen J. I., Thomas E., Prussin C. et al. (1998) CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. **161:** 4563–4571
459 Chaussabel D., Jacobs F., Jonge J. de, Veerman M. de, Carlier Y., Thielemans K. et al. (1999) CD40 ligation prevents *Trypanosema cruzi* infection through interleukin-12 upregulation. Infect. Immun. **67:** 1929–1934
460 Campos-Neto A., Ovendale P., Bement T., Koppi T. A., Fanslow W. C., Rossi M. A. et al. (1998) CD40 ligand is not essential for the development of cell-mediated immunity and resistance to *Mycobacterium tuberculosis*. J. Immunol. **160:** 2037–2041
461 Parker D. C., Greiner D. L., Phillips N. E., Appel M. C., Steele A. W., Durie F. H. et al. (1995) Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc. Natl. Acad. Sci. USA **92:** 9560–9564
462 Larsen C. P., Elwood E. T., Alexander D. Z., Ritchie S. C., Hendrix R., Tucker-Burden C. et al. (1996) Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature **381:** 434–438
463 Hancock W. W., Sayegh M. H., Zheng X. G., Peach R., Linsley P. S. and Turka L. A. (1996) Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA **93:** 13967–13972
464 Markees T. G., Phillips N. E., Noelle R. J., Shultz L. D., Mordes J. P., Greiner D. L. et al. (1997) Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation **64:** 329–335
465 Funakoshi S., Taub D. D., Anver M. R., Raziuddin A., Asai O., Reddy V. et al. (1997) Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. J. Clin. Invest. **99:** 484–491
466 Blazer B. R., Taylor P. A., Panoskaltsis-Mortari A., Buhlman J., Xu J., Flavell R. A. et al. (1997) Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J. Immunol. **158:** 29–39
467 Elwood E. T., Larsen C. P., Cho H. R., Corbascio M., Ritchie S. C., Alexander D. Z. et al. (1998) Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation **65:** 1422–1428
468 Kirk A. D., Harlan D. M., Armstrong N. N., Davis T. A., Dong Y., Gray G. S. et al. (1997) CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA **94:** 8789–8794
469 Sun H., Subbotin V., Chen C., Aitouche A., Valdivia L. A., Sayegh M. H. et al. (1997) Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation **64:** 1838–1843
470 Saito K., Sakurai J., Ohata J., Kohsaka T., Hashimoto H., Okumura K. et al. (1998) Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J. Immunol. **160:** 4225–4231
471 Markees T. G., Phillips N. E., Gordon E. J., Noelle R. J., Shultz L. D., Mordes J. P. et al. (1998) Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J. Clin. Invest. **101:** 2446–2455
472 Kirk A. D., Burkly L. C., Batty D. S., Baumgartner R. E., Berming J. D., Buchanan K. et al. (1999) Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. **5:** 686–693
473 Larsen C. P. and Pearson T. C. (1997) The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr. Opin. Immunol. **9:** 641–647
474 Konieczny B. T., Dai Z., Elwood E. T., Saleem S., Linsley P. S., Baddoura F. K. et al. (1998) IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J. Immunol. **160:** 2059–2064
475 Flamand V., Donckier V., Demoor F. X., Le Moine A., Matthys P., Vanderhaeghen M. L. et al. (1998) CD40 ligation prevents neonatal induction of transplantation tolerance. J. Immunol. **160:** 4666–4669
476 Hancock W. W., Buelow R., Sayegh M. H. and Turka L. A. (1998) Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat. Med. **4:** 1392–1396
477 Gaweco A. S., Wiesner R. H., Yong S., Krom R., Porayko M., Chejfec G. et al. (1999) Kupffer cell expression of CD40L (CD154) in human chronic liver allograft rejection. Transplant Proc. **31:** 560–561
478 Mohan C., Shi Y., Laman J. D. and Datta S. K. (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. **154:** 1470–1480

479 Ma J., Xu J., Madaio M. P., Peng Q., Zhang J., Grewal I. S. et al. (1996) Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J. Immunol. **157:** 417–426
480 Durie F. H., Flavell R. A. and Noelle R. J. (1994) Collagen-induced arthritis as a model of rheumatoid arthritis. Clin. Immunol. Immunopathol. **73:** 11–18
481 Grewal I. S., Foellmer H. G., Grewal K. D., Xu J., Hardardottir F., Baron J. L. et al. (1996) Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science **273:** 1864–1867
482 Samoilova E. B., Horton J. L., Zhang H. and Chen Y. (1997) CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation. J. Mol. Med. **75:** 603–608
483 Gerritse K., Laman J. D., Noelle R. J., Aruffo A., Ledbetter J. A., Boersma W. J. et al. (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA **93:** 2499–2504
484 Laman J. D., Maassen C. B., Schellekens M. M., Visser L., Kap M., Jong E. de et al. (1998) Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide. Multiple Sclerosis **4:** 147–153
485 Datta S. K. and Kalled S. L. (1997) CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. **40:** 1735–1745
486 Balasa B., Krahl T., Patstone G., Lee J., Tisch R., McDevitt H. O. et al. (1997) CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. **159:** 4620–4627
487 Early G. S., Zhao W. and Burns C. M. (1996) Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice: response correlates with the absence of an anti-antibody response. J. Immunol. **157:** 3159–3164
488 Peng S. L., McNiff J. M., Madio M. P., Ma J., Owen M. J., Flavell R. A. et al. (1997) Alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J. Immunol. **158:** 2464–2470
489 Rathmell J. C., Townsend S. E., Xu J. C., Flavell R. A. and Goodnow C. C. (1996) Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell **87:** 319–329
490 Hirose S., Yan K., Abe M., Jiang Y., Hamano Y., Tsurui H. et al. (1997) Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination. Proc. Natl. Acad. Sci. USA **94:** 9291–9295
491 Stuber E., Strober W. and Neurath M. (1996) Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. **183:** 693–698
492 Caspi R. R. (1998) IL-12 in autoimmunity. Clin. Immunol. Immunopathol. **88:** 4–13
493 Harigai M., Hara M., Nakazawa S., Fukasawa C., Ohta S., Sugiura T. et al. (1999) Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. J. Rheumatol. **26:** 1035–1043
494 Koshy M., Berger D. and Crow M. K. (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. **98:** 826–837
495 Sekine C., Yagita H., Miyasaka N. and Okumura K. (1998) Expression and function of CD40 in rheumatoid arthritis synovium. J. Rheumatol. **25:** 1048–1053
496 Wagner U. G., Kurtin P. J., Wahner A., Brackertz M., Berry D. J., Goronzy J. J. et al. (1998) The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J. Immunol. **161:** 6390–6397
497 MacDonald K. P., Nishioka Y., Lipsky P. E. and Thomas R. (1997) Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J. Clin. Invest. **100:** 2404–2414
498 Sibilia J., Durandy A., Schaeverbeke T. and Fermand J. P. (1996) Hyper-IgM syndrome associated with rheumatoid arthritis: report of RA in a patient with primary impaired CD40 pathway. Br. J. Rheumatol. **35:** 282–284
499 Webster E. A., Khakoo A. Y., Mackus W. J., Karpusas M., Thomas D. W., Davidson A. et al. (1999) An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome). Arthritis. Rheum. **42:** 1291–1296
500 Schönbeck U., Sukhova G. K., Herman M., Graber P., Kehry M. R. and Libby P. (2000) CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am. J. Pathol. **156:** 7–14
501 Boer O. J. de, Wal A. C. van der, Teeling P. and Becker A. E. (1999) Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc. Res. **41:** 443–449
502 Terkeltaub R., Boisvert W. A. and Curtiss L. K. (1998) Chemokines and atherosclerosis. Curr. Opin. Lipidol. **9:** 397–405
503 Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M. and DuBois R. N. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell **93:** 705–716
504 Lutgens E., Gorelik L., Daemen M. J., Muinck E. D. de, Grewal I. S., Koteliansky V. E. et al. (1999) Requirement for CD154 in the progression of atherosclerosis. Nat. Med. **5:** 1313–1316
505 Aukrust P., Muller F., Ueland T., Berget T., Aaser E., Brunsvig A. et al. (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation **100:** 614–620
506 Ross R. (1999) Atherosclerosis—an inflammatory disease. N. Engl. J. Med. **340:** 115–126
507 Sakata-Kaneko S., Wakatsuki Y., Usui T., Matsunaga Y., Itoh T., Nishi E. et al. (1998) Lysophosphatidylcholine upregulates CD40 ligand expression in newly activated human CD4+ T cells. FEBS Lett. **433:** 161–165
508 Tong A. W., Zhang B. Q., Mues G., Solano M., Hanson T. and Stone M. J. (1994) Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood **84:** 3026–3033
509 Carbone A., Gloghini A., Gruss H. J. and Pinto A. (1995) CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am. J. Pathol. **147:** 912–922
510 Thomas W. D., Smith M. J., Si Z. and Hersey P. (1996) Expression of the co-stimulatory molecule CD40 on melanoma cells. Int. J. Cancer **68:** 795–801
511 Cooke P. W., James N. D., Ganesan R., Wallace M., Burton A. and Young L. S. (1999) CD40 expression in bladder cancer. J. Pathol. **188:** 38–43
512 Romano M. F., Lamberti A., Tassone P., Alfinito F., Costantini S., Chiurazzi F. et al. (1998) Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood **92:** 990–995
513 Crawford D. H. and Catovsky D. (1993) In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology **80:** 40–44
514 Planken E. V., Dijkstra N. H., Bakkus M., Willemze R. and Kluin-Nelemans J. C. (1996) Proliferation of precursor B-lineage acute lymphoblastic leukaemia by activating the CD40 antigen. Br. J. Haematol. **95:** 319–326
515 Santos-Argumedo L., Gordon J., Heath A. W. and Howard M. (1994) Antibodies to murine CD40 protect normal and malignant B cells from induced growth arrest. Cell. Immunol. **156:** 272–285
516 Metkar S. S., Naresh K. N., Redkar A. A. and Nadkarni J. J. (1998) CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line. Cancer Immunol. Immunother. **47:** 104–112

517 Cantwell M., Hua T., Pappas J. and Kipps T. J. (1997) Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat. Med. **3:** 984–989
518 Funakoshi S., Longo D. L., Beckwith M., Conley D. K., Tsarfaty G., Tsarfaty I. et al. (1994) Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood **83:** 2787–2794
519 Murphy W. J., Funakoshi S., Beckwith M., Rushing S. E., Conley D. K., Armitage R. J. et al. (1995) Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood **86:** 1946–1953
520 Mackey M. F., Gunn J. R., Ting P. P., Kikutani H., Dranoff G., Noelle R. J. et al. (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. **57:** 2569–2574
521 Mackey M. F., Gunn J. R., Maliszewsky C., Kikutani H., Noelle R. J. and Barth R. J. Jr (1998) Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. **161:** 2094–2098
522 French R. R., Chan H. T., Tutt A. L. and Glennie M. J. (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. **5:** 548–553
523 Nakajima A., Kodama T., Morimoto S., Azuma M., Takeda K., Oshima H. et al. (1998) Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. **161:** 1901–1907
524 Grossmann M. E., Brown M. P. and Brenner M. K. (1997) Antitumor responses induced by transgenic expression of CD40 ligand. Hum. Gene Ther. **8:** 1935–1943
525 Kato K., Cantwell M. J., Sharma S. and Kipps T. J. (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest. **101:** 1133–1141
526 Labeur M. S., Roters B., Pers B., Mehling A., Luger T. A., Schwarz T. et al. (1999) Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. **162:** 168–175
527 Kikuchi T. and Crystal R. G. (1999) Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum. Gene Ther. **10:** 1375–1387
528 Imaizumi K., Kawabe T., Ichiyama S., Kikutani H., Yagita H., Shimokata K. et al. (1999) Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. Am. J. Physiol. **277:** L49–57
529 Brown M. P., Topham D. J., Sangster M. Y., Zhao J., Flynn K. J., Surman S. L. et al. (1998) Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. **4:** 1253–1260
530 Francisco J. A., Gilliland L. K., Stebbins M. R., Norris N. A., Ledbetter J. A. and Siegall C. B. (1995) Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res. **55:** 3099–3104
531 Francisco J. A., Schreiber G. J., Comereski C. R., Mezza L. E., Warner G. L., Davidson T. J. et al. (1997) In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood **89:** 4493–4500
532 Soler P., Boussaud V., Moreau J., Bergeron A., Bonnette P., Hance A. J. et al. (1999) In situ expression of B7 and CD40 costimulatory molecules by normal human lung macrophages and epithelioid cells in tuberculoid granulomas. Clin. Exp. Immunol. **116:** 332–339
533 Lei X. F., Ohkawara Y., Stampfli M. R., Mastruzzo C., Marr R. A., Snider D. et al. (1998) Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J. Clin. Invest. **101:** 1342–1353
534 Wiley J. A., Geha R. and Harmsen A. G. (1997) Exogenous CD40 ligand induces a pulmonary inflammation response. J. Immunol. **158:** 2932–2938
535 Hogan S. P., Mould A., Kikutani H., Ramsay A. J. and Foster P. S. (1997) Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J. Clin. Invest. **99:** 1329–1339
536 Wiley J. A. and Harmsen A. G. (1999) Bone marrow-derived cells are required for the induction of a pulmonary inflammatory response mediated by CD40 ligation. Am. J. Pathol. **154:** 919–926
537 Adawi A., Zhang Y., Baggs R., Rubin P., Williams J., Finkelstein J. et al. (1998) Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin. Immunol. Immunopathol. **89:** 222–230